drTarget portfolio target-disease associations for gastrointestinal diseases DrTarget’s AI-Powered Indication Expansion for Gastrointestinal Diseases

AI-Driven Drug Discovery for Gastrointestinal Diseases

DrTarget harnesses advanced AI and bioinformatics to uncover novel disease-target associations for gastrointestinal (GI) disorders. Using machine learning and pathway analysis, we identify new therapeutic opportunities for:

✔ Inflammatory Bowel Disease (IBD) – Discovering novel targets for Crohn’s disease and ulcerative colitis.
✔ Liver Diseases – Identifying compounds for NAFLD, NASH, and liver fibrosis.
✔ Gastrointestinal Cancers – Enhancing drug discovery for colorectal, gastric, and pancreatic cancers.
✔ Microbiome-Linked Disorders – Exploring AI-based insights into gut microbiota interactions.

Target-disease associations for gastrointestinal diseases.

Check best scored target-disease associations in table:

BioAssay Name	program	diseaseName	assayType	associationScore	numberOfEvidences	testedCompounds	activeCompounds
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	Barrett's esophagus	targetBased	0.235228761404003	20	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	Barrett's esophagus	targetBased	0.235228761404003	20	296501	2737
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Barrett's esophagus	pathwayBased	0.330975192177869	416	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Barrett's esophagus	targetBased	0.330975192177869	416	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Barrett's esophagus	targetBased	0.330975192177869	416	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Barrett's esophagus	targetBased	0.330975192177869	416	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Barrett's esophagus	targetBased	0.330975192177869	416	124022	1156
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	irritable bowel syndrome	targetBased	0.322758795135049	18	290355	265
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	irritable bowel syndrome	targetBased	0.419910414935912	5	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	irritable bowel syndrome	targetBased	0.609584926847712	24	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	irritable bowel syndrome	targetBased	0.609584926847712	24	335239	695
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	0.571601682713427	23	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	0.571601682713427	23	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	0.571601682713427	23	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	0.571601682713427	23	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	0.571601682713427	23	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	irritable bowel syndrome	targetBased	0.571601682713427	23	196177	519
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	irritable bowel syndrome	targetBased	0.578284034396309	9	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	irritable bowel syndrome	targetBased	0.578284034396309	9	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	irritable bowel syndrome	targetBased	0.578284034396309	9	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	irritable bowel syndrome	targetBased	0.578284034396309	9	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	irritable bowel syndrome	targetBased	0.578284034396309	9	359207	4555
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	irritable bowel syndrome	targetBased	0.557687575050289	12	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	irritable bowel syndrome	targetBased	0.557687575050289	12	61606	416
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	irritable bowel syndrome	targetBased	0.304485764646766	5	104728	4230
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	irritable bowel syndrome	targetBased	0.110654655228409	78	316642	617
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	salivary gland neoplasm	targetBased	0.466551012569262	19	194628	267
HCS assay for microtubule stabilizers	TUBB	salivary gland neoplasm	targetBased	0.110381587894355	13	195821	1625
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	necrotizing enterocolitis	targetBased	0.115710864248473	20	330392	1295
qHTS for Inhibitors of TGF-b	TGFB1	eosinophilic esophagitis	pathwayBased	0.104207403721309	92	403345	4970
qHTS assay for re-activators of p53 using a Luc reporter	TP53	salivary gland neoplasm	pathwayBased	0.177738024780621	69	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	salivary gland neoplasm	targetBased	0.177738024780621	69	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	salivary gland neoplasm	targetBased	0.177738024780621	69	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	salivary gland neoplasm	targetBased	0.177738024780621	69	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	salivary gland neoplasm	targetBased	0.177738024780621	69	124022	1156
HTS of Smad transcription factor inhibitors	SMAD3	eosinophilic esophagitis	targetBased	0.346515606232344	6	88033	251
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	gastroesophageal reflux disease	targetBased	0.317249223731667	8	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	gastroesophageal reflux disease	targetBased	0.317249223731667	8	86095	1151
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	gastroesophageal reflux disease	targetBased	0.611643521081338	12	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	gastroesophageal reflux disease	targetBased	0.611643521081338	12	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	gastroesophageal reflux disease	targetBased	0.611643521081338	12	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	gastroesophageal reflux disease	targetBased	0.611643521081338	12	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	gastroesophageal reflux disease	targetBased	0.611643521081338	12	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gastroesophageal reflux disease	targetBased	0.611643521081338	12	336308	6862
Assay for HTS of Gi/Go-linked GPCRs using mGluR8: Primary Screening	GRM8	gastroesophageal reflux disease	targetBased	0.377619787484508	6	105151	2166
Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity	KDM4C	gut microbiome measurement	targetBased	0.145279842104166	5	326066	228
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	dyspepsia	targetBased	0.614594595559056	21	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	dyspepsia	targetBased	0.614594595559056	21	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	dyspepsia	targetBased	0.614594595559056	21	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	dyspepsia	targetBased	0.614594595559056	21	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	dyspepsia	targetBased	0.614594595559056	21	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	dyspepsia	targetBased	0.614594595559056	21	336308	6862
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	intestinal disease	targetBased	0.16236887339206	186	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	intestinal disease	targetBased	0.16236887339206	186	296501	2737
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	intestinal disease	targetBased	0.190247174158658	206	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	intestinal disease	targetBased	0.190247174158658	206	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	intestinal disease	targetBased	0.273474001557521	154	217959	2390
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	intestinal disease	targetBased	0.166424068651822	38	290726	671
qHTS for Inhibitors of TGF-b	TGFB1	intestinal disease	pathwayBased	0.191051208401801	965	403345	4970
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	intestinal disease	targetBased	0.183943869471892	85	57013	201
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	intestinal disease	targetBased	0.134425221143952	356	324747	7988
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	intestinal disease	pathwayBased	0.188886131983759	1943	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	intestinal disease	pathwayBased	0.188886131983759	1943	359244	3094
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	intestinal disease	targetBased	0.22533214842089	237	394050	3624
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	intestinal disease	targetBased	0.159558530675666	1437	67275	2509
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	intestinal disease	targetBased	0.223801507523021	66	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	intestinal disease	targetBased	0.223801507523021	66	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	intestinal disease	targetBased	0.165678384527367	45	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	intestinal disease	targetBased	0.165678384527367	45	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	intestinal disease	targetBased	0.165678384527367	45	405130	6428
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	intestinal disease	pathwayBased	0.309480347410475	434	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	intestinal disease	targetBased	0.309480347410475	434	195980	695
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	intestinal disease	targetBased	0.19875880597046	57	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	intestinal disease	targetBased	0.184464351752167	91	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	intestinal disease	pathwayBased	0.184464351752167	91	403871	1243
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	intestinal disease	targetBased	0.184367571936416	37	363803	458
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	intestinal disease	targetBased	0.108088473305537	195	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	intestinal disease	targetBased	0.108088473305537	195	335180	1022
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	intestinal disease	targetBased	0.285245238122266	509	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	intestinal disease	targetBased	0.285245238122266	509	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	intestinal disease	targetBased	0.285245238122266	509	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	intestinal disease	targetBased	0.285245238122266	509	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	intestinal disease	targetBased	0.285245238122266	509	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	intestinal disease	targetBased	0.285245238122266	509	196177	519
qHTS assay for re-activators of p53 using a Luc reporter	TP53	intestinal disease	pathwayBased	0.313419734715544	1889	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	intestinal disease	targetBased	0.313419734715544	1889	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	intestinal disease	targetBased	0.313419734715544	1889	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	intestinal disease	targetBased	0.313419734715544	1889	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	intestinal disease	targetBased	0.313419734715544	1889	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	intestinal disease	targetBased	0.256767340162127	593	356517	1139
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	intestinal disease	targetBased	0.111457367425371	28	325630	216
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	intestinal disease	targetBased	0.111468945751082	246	326024	350
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	intestinal disease	targetBased	0.324110275625142	1213	292323	1836
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	intestinal disease	targetBased	0.395175882863495	12	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	intestinal disease	targetBased	0.395175882863495	12	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	intestinal disease	targetBased	0.395175882863495	12	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	intestinal disease	targetBased	0.395175882863495	12	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	intestinal disease	targetBased	0.395175882863495	12	359207	4555
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	intestinal disease	pathwayBased	0.210477469754348	774	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	intestinal disease	pathwayBased	0.210477469754348	774	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	intestinal disease	targetBased	0.172857872797247	15	339297	1446
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	intestinal disease	targetBased	0.151147465092598	43	218654	8241
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	intestinal disease	targetBased	0.193425486897253	31	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	intestinal disease	targetBased	0.193425486897253	31	331360	2760
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	intestinal disease	targetBased	0.19821201084393	144	316642	617
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	intestinal disease	pathwayBased	0.252632519252451	296	43989	342
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	fecal incontinence	targetBased	0.543359118242622	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	fecal incontinence	targetBased	0.543359118242622	6	335239	695
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	biliary tract disease	targetBased	0.125954934868726	10	194152	1342
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	biliary tract disease	targetBased	0.185763128377747	68	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	biliary tract disease	targetBased	0.185763128377747	68	86095	1151
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	biliary tract disease	targetBased	0.112243454341494	7	386270	1331
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	disease of peritoneum	pathwayBased	0.181819499029054	77	376029	3978
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	disease of peritoneum	targetBased	0.160705135248287	25	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	disease of peritoneum	targetBased	0.160705135248287	25	86095	1151
qHTS assay for re-activators of p53 using a Luc reporter	TP53	disease of peritoneum	pathwayBased	0.169623621717477	108	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disease of peritoneum	targetBased	0.169623621717477	108	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disease of peritoneum	targetBased	0.169623621717477	108	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disease of peritoneum	targetBased	0.169623621717477	108	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disease of peritoneum	targetBased	0.169623621717477	108	124022	1156
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	esophageal varices	targetBased	0.57280694202758	8	339297	1446
qHTS of IL-2 Activators	IL2	malabsorption syndrome	targetBased	0.165804278457421	40	364617	238
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	malabsorption syndrome	targetBased	0.15422425171287	6	358434	2554
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	stomach disease	targetBased	0.148228038380256	6	336894	489
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	stomach disease	targetBased	0.226248720210366	55	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	stomach disease	targetBased	0.226248720210366	55	86095	1151
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	stomach disease	targetBased	0.169495776447095	14	359207	1432
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	stomach disease	targetBased	0.158064897594836	16	57013	201
E3 Ligase HTS_1536	MDM2	stomach disease	targetBased	0.169197340629072	29	207811	220
qHTS assay for re-activators of p53 using a Luc reporter	TP53	stomach disease	pathwayBased	0.301248975474893	552	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	stomach disease	targetBased	0.301248975474893	552	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	stomach disease	targetBased	0.301248975474893	552	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	stomach disease	targetBased	0.301248975474893	552	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	stomach disease	targetBased	0.301248975474893	552	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	stomach disease	targetBased	0.18309160563804	141	356517	1139
HTS of Smad transcription factor inhibitors	SMAD3	stomach disease	targetBased	0.150959091189651	11	88033	251
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	stomach disease	pathwayBased	0.177437817873502	82	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	stomach disease	pathwayBased	0.177437817873502	82	194666	1722
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	stomach disease	pathwayBased	0.200037104961387	64	43989	342
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	gastrointestinal disease	targetBased	0.338673280198078	752	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	gastrointestinal disease	targetBased	0.338673280198078	752	296501	2737
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	gastrointestinal disease	targetBased	0.549751654009714	39	290355	265
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the drug-selected MDR subline cells KB-V1	MDR1-selectiveÃ‚Â compounds	gastrointestinal disease	targetBased	0.103336312144793	479	396029	13426
qHTS assay for MDR1-selective chemotherapeutics: Primary screen using the parental adenocarcinoma cell KB-3-1	MDR1-selectiveÃ‚Â compounds	gastrointestinal disease	targetBased	0.103336312144793	479	395981	5516
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	gastrointestinal disease	targetBased	0.298709473653827	203	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	gastrointestinal disease	targetBased	0.298709473653827	203	337446	1356
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	gastrointestinal disease	targetBased	0.280710885313529	1047	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	gastrointestinal disease	targetBased	0.280710885313529	1047	86095	1151
qHTS for Inhibitors of TGF-b	TGFB1	gastrointestinal disease	pathwayBased	0.218983632603833	5317	403345	4970
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	gastrointestinal disease	targetBased	0.138082050917971	782	324747	7988
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	gastrointestinal disease	pathwayBased	0.203873417453037	5969	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	gastrointestinal disease	pathwayBased	0.203873417453037	5969	359244	3094
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	gastrointestinal disease	targetBased	0.254736303304555	874	394050	3624
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	gastrointestinal disease	targetBased	0.159294284204697	4482	67275	2509
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gastrointestinal disease	targetBased	0.626780891642088	146	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gastrointestinal disease	targetBased	0.626780891642088	146	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	gastrointestinal disease	targetBased	0.278303064132598	4612	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	gastrointestinal disease	targetBased	0.278303064132598	4612	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	gastrointestinal disease	targetBased	0.278303064132598	4612	405130	6428
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	gastrointestinal disease	pathwayBased	0.311829263265792	836	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	gastrointestinal disease	targetBased	0.311829263265792	836	195980	695
qHTS for Inhibitors of Inflammasome Signaling: IL-1-beta AlphaLISA Primary Screen	IL-1b Inflammasome	gastrointestinal disease	pathwayBased	0.151421656658236	5514	362051	17187
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastrointestinal disease	targetBased	0.375465575819017	3259	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastrointestinal disease	targetBased	0.375465575819017	3259	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastrointestinal disease	targetBased	0.375465575819017	3259	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastrointestinal disease	targetBased	0.375465575819017	3259	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastrointestinal disease	targetBased	0.375465575819017	3259	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastrointestinal disease	targetBased	0.375465575819017	3259	196177	519
VEID(2) R110 Enzymatic Primary HTS to identify Inhibitors of Caspase 6 Measured in Biochemical System Using Plate Reader - 7052-01_Inhibitor_SinglePoint_HTS_Activity_Set2	Caspase6Inhibitors	gastrointestinal disease	targetBased	0.12979173562019	37	344318	1854
qHTS assay for re-activators of p53 using a Luc reporter	TP53	gastrointestinal disease	pathwayBased	0.329006687360773	8564	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastrointestinal disease	targetBased	0.329006687360773	8564	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastrointestinal disease	targetBased	0.329006687360773	8564	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastrointestinal disease	targetBased	0.329006687360773	8564	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastrointestinal disease	targetBased	0.329006687360773	8564	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	gastrointestinal disease	targetBased	0.26636181111914	5746	356517	1139
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	gastrointestinal disease	targetBased	0.406070807924668	7	292323	567
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	gastrointestinal disease	targetBased	0.630154237489178	108	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	gastrointestinal disease	targetBased	0.630154237489178	108	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	gastrointestinal disease	targetBased	0.630154237489178	108	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	gastrointestinal disease	targetBased	0.630154237489178	108	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	gastrointestinal disease	targetBased	0.630154237489178	108	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gastrointestinal disease	targetBased	0.630154237489178	108	336308	6862
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	gastrointestinal disease	targetBased	0.552312264766224	68	335531	328
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	gastrointestinal disease	targetBased	0.118840680082599	2239	330392	1295
uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase	ALPI_inhibitors	gastrointestinal disease	targetBased	0.19138442576141	40	330392	393
uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase	ALPI_inhibitors	gastrointestinal disease	targetBased	0.19138442576141	40	331670	664
Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase	ALPI_activators	gastrointestinal disease	targetBased	0.19138442576141	40	195570	326
uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase	ALPI_activators	gastrointestinal disease	targetBased	0.19138442576141	40	330392	537
uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase	ALPI_activators	gastrointestinal disease	targetBased	0.19138442576141	40	331670	785
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	gastrointestinal disease	targetBased	0.149094352026461	1461	326024	350
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	gastrointestinal disease	targetBased	0.422744545189202	4	40473	1400
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	gastrointestinal disease	targetBased	0.333536313063467	1311	292323	1836
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	gastrointestinal disease	targetBased	0.647353283120319	44	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	gastrointestinal disease	targetBased	0.647353283120319	44	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	gastrointestinal disease	targetBased	0.647353283120319	44	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	gastrointestinal disease	targetBased	0.647353283120319	44	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	gastrointestinal disease	targetBased	0.647353283120319	44	359207	4555
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	gastrointestinal disease	pathwayBased	0.274561257666288	2850	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	gastrointestinal disease	pathwayBased	0.274561257666288	2850	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	gastrointestinal disease	targetBased	0.230047515561731	118	339297	1446
Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).	BCL2L1_modulators	gastrointestinal disease	targetBased	0.124423196455013	398	314998	2199
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	gastrointestinal disease	targetBased	0.232995771004277	35	369953	760
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	gastrointestinal disease	targetBased	0.232995771004277	35	369953	498
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	gastrointestinal disease	targetBased	0.284832737223483	30	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	gastrointestinal disease	targetBased	0.284832737223483	30	61606	416
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	gastrointestinal disease	targetBased	0.492691737550043	9	363803	1450
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	gastrointestinal disease	targetBased	0.492691737550043	9	363803	2629
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	gastrointestinal disease	targetBased	0.492691737550043	9	363803	502
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	gastrointestinal disease	targetBased	0.490885862309666	7	363803	698
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	gastrointestinal disease	targetBased	0.490885862309666	7	363803	2133
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	gastrointestinal disease	targetBased	0.490885862309666	7	363803	1081
HCS assay for microtubule stabilizers	TUBB	gastrointestinal disease	targetBased	0.285951021888019	730	195821	1625
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	gastrointestinal disease	targetBased	0.449925211715772	23	104728	4230
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	gastrointestinal disease	targetBased	0.286693450126032	377	316642	617
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	hepatobiliary disease	targetBased	0.182876083519353	82	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	hepatobiliary disease	targetBased	0.182876083519353	82	296501	2737
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatobiliary disease	targetBased	0.278278862478759	668	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatobiliary disease	targetBased	0.278278862478759	668	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatobiliary disease	targetBased	0.278278862478759	668	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatobiliary disease	targetBased	0.278278862478759	668	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatobiliary disease	targetBased	0.278278862478759	668	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	hepatobiliary disease	targetBased	0.278278862478759	668	196177	519
E3 Ligase HTS_1536	MDM2	hepatobiliary disease	targetBased	0.226144721997156	175	207811	220
qHTS assay for re-activators of p53 using a Luc reporter	TP53	hepatobiliary disease	pathwayBased	0.31053149872031	3174	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hepatobiliary disease	targetBased	0.31053149872031	3174	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hepatobiliary disease	targetBased	0.31053149872031	3174	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hepatobiliary disease	targetBased	0.31053149872031	3174	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	hepatobiliary disease	targetBased	0.31053149872031	3174	124022	1156
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Salivary Gland Pleomorphic Adenoma	pathwayBased	0.306057893011864	5	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Salivary Gland Pleomorphic Adenoma	targetBased	0.306057893011864	5	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Salivary Gland Pleomorphic Adenoma	targetBased	0.306057893011864	5	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Salivary Gland Pleomorphic Adenoma	targetBased	0.306057893011864	5	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Salivary Gland Pleomorphic Adenoma	targetBased	0.306057893011864	5	124022	1156
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	Salivary Gland Pleomorphic Adenoma	targetBased	0.407840526197416	5	193542	587
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Colon Dysplasia	pathwayBased	0.203615980189334	5	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Colon Dysplasia	targetBased	0.203615980189334	5	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Colon Dysplasia	targetBased	0.203615980189334	5	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Colon Dysplasia	targetBased	0.203615980189334	5	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Colon Dysplasia	targetBased	0.203615980189334	5	124022	1156
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	burning mouth syndrome	targetBased	0.409331474917967	23	316642	617
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	gastroparesis	targetBased	0.609010949181426	33	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	gastroparesis	targetBased	0.609010949181426	33	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	gastroparesis	targetBased	0.609010949181426	33	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	gastroparesis	targetBased	0.609010949181426	33	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	gastroparesis	targetBased	0.609010949181426	33	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gastroparesis	targetBased	0.609010949181426	33	336308	6862
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	mouth disease	targetBased	0.145216007258082	54	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	mouth disease	targetBased	0.145216007258082	54	86095	1151
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	mouth disease	targetBased	0.189030769016559	89	394050	3624
qHTS assay for re-activators of p53 using a Luc reporter	TP53	mouth disease	pathwayBased	0.22524520621551	643	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	mouth disease	targetBased	0.22524520621551	643	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	mouth disease	targetBased	0.22524520621551	643	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	mouth disease	targetBased	0.22524520621551	643	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	mouth disease	targetBased	0.22524520621551	643	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	mouth disease	targetBased	0.1449037414548	359	356517	1139
HTS of Smad transcription factor inhibitors	SMAD3	mouth disease	targetBased	0.13858440843348	14	88033	251
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	gastroenteritis	targetBased	0.108998147043946	81	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	gastroenteritis	targetBased	0.108998147043946	81	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	gastroenteritis	targetBased	0.255744328287688	76	217959	2390
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	gastroenteritis	targetBased	0.110274934508659	28	57013	201
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	gastroenteritis	targetBased	0.124113249622636	207	324747	7988
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	gastroenteritis	pathwayBased	0.178821024895133	1089	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	gastroenteritis	pathwayBased	0.178821024895133	1089	359244	3094
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	gastroenteritis	targetBased	0.155693653512334	774	67275	2509
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gastroenteritis	targetBased	0.144951058771754	13	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	gastroenteritis	targetBased	0.144951058771754	13	335239	695
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastroenteritis	targetBased	0.236302572320261	274	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastroenteritis	targetBased	0.236302572320261	274	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastroenteritis	targetBased	0.236302572320261	274	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastroenteritis	targetBased	0.236302572320261	274	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastroenteritis	targetBased	0.236302572320261	274	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	gastroenteritis	targetBased	0.236302572320261	274	196177	519
qHTS assay for re-activators of p53 using a Luc reporter	TP53	gastroenteritis	pathwayBased	0.113098173508316	236	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastroenteritis	targetBased	0.113098173508316	236	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastroenteritis	targetBased	0.113098173508316	236	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastroenteritis	targetBased	0.113098173508316	236	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	gastroenteritis	targetBased	0.113098173508316	236	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	gastroenteritis	targetBased	0.112720450499552	198	356517	1139
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	gastroenteritis	pathwayBased	0.138608902911651	33	7671	874
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	gastroenteritis	targetBased	0.138608902911651	33	304060	10600
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	gastroenteritis	pathwayBased	0.138608902911651	33	305439	16717
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	gastroenteritis	targetBased	0.562663370717272	11	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	gastroenteritis	targetBased	0.562663370717272	11	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	gastroenteritis	targetBased	0.562663370717272	11	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	gastroenteritis	targetBased	0.562663370717272	11	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	gastroenteritis	targetBased	0.562663370717272	11	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	gastroenteritis	targetBased	0.562663370717272	11	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	gastroenteritis	targetBased	0.106680740940599	16	322361	619
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	gastroenteritis	targetBased	0.119241205060252	4	335777	499
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	gastroenteritis	targetBased	0.274271028756649	220	292323	1836
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	gastroenteritis	pathwayBased	0.124240109384012	366	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	gastroenteritis	pathwayBased	0.124240109384012	366	194666	1722
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	gastroenteritis	pathwayBased	0.143803635544244	95	43989	342
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	gastroenteritis	targetBased	0.120926352110174	74	343468	734
uHTS Luminescent assay for identification of inhibitors of NALP3 in yeast	NLRP3	Oral ulcer	targetBased	0.259137631040282	8	330392	1295
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Vomiting	targetBased	0.442111797582819	8	363803	2412
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Vomiting	targetBased	0.607745142219739	20	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Vomiting	targetBased	0.607745142219739	20	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Vomiting	targetBased	0.607745142219739	20	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Vomiting	targetBased	0.607745142219739	20	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Vomiting	targetBased	0.607745142219739	20	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Vomiting	targetBased	0.607745142219739	20	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	Vomiting	targetBased	0.439677534307829	6	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	Vomiting	targetBased	0.439677534307829	6	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	Vomiting	targetBased	0.439677534307829	6	407539	2380
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	Diarrhea	targetBased	0.594015846742141	46	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	Diarrhea	targetBased	0.594015846742141	46	296501	2737
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Diarrhea	targetBased	0.664483849517651	134	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Diarrhea	targetBased	0.664483849517651	134	335239	695
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	Diarrhea	targetBased	0.587578994481585	15	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	Diarrhea	targetBased	0.587578994481585	15	335180	1022
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	Dysphagia	targetBased	0.141863454192519	5	108286	1415
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Gastrointestinal hemorrhage	targetBased	0.485319970713906	5	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Gastrointestinal hemorrhage	targetBased	0.485319970713906	5	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Gastrointestinal hemorrhage	targetBased	0.485319970713906	5	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Gastrointestinal hemorrhage	targetBased	0.485319970713906	5	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Gastrointestinal hemorrhage	targetBased	0.485319970713906	5	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Gastrointestinal hemorrhage	targetBased	0.485319970713906	5	336308	6862
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Peptic ulcer	targetBased	0.624294296119937	14	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Peptic ulcer	targetBased	0.624294296119937	14	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Peptic ulcer	targetBased	0.624294296119937	14	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Peptic ulcer	targetBased	0.624294296119937	14	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Peptic ulcer	targetBased	0.624294296119937	14	359207	4555
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the gastrointestinal tract	targetBased	0.175508109727307	14	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the gastrointestinal tract	targetBased	0.175508109727307	14	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the gastrointestinal tract	targetBased	0.175508109727307	14	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the gastrointestinal tract	targetBased	0.175508109727307	14	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the gastrointestinal tract	targetBased	0.175508109727307	14	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the gastrointestinal tract	targetBased	0.175508109727307	14	196177	519
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	cholestasis	targetBased	0.512356311300188	11	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	cholestasis	targetBased	0.512356311300188	11	296501	2737
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	cholestasis	targetBased	0.256611920238613	5	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	cholestasis	targetBased	0.256611920238613	5	337446	1356
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	constipation disorder	targetBased	0.577168330395272	6	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	constipation disorder	targetBased	0.577168330395272	6	335239	695
qHTS assay for re-activators of p53 using a Luc reporter	TP53	esophagitis	pathwayBased	0.204041187380841	4	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophagitis	targetBased	0.204041187380841	4	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophagitis	targetBased	0.204041187380841	4	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophagitis	targetBased	0.204041187380841	4	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophagitis	targetBased	0.204041187380841	4	124022	1156
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	bile duct disorder	targetBased	0.17334226668571	38	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	bile duct disorder	targetBased	0.17334226668571	38	86095	1151
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	bile duct disorder	pathwayBased	0.118169891203577	76	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	bile duct disorder	pathwayBased	0.118169891203577	76	359244	3094
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diverticulitis	targetBased	0.375440031217794	6	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diverticulitis	targetBased	0.375440031217794	6	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diverticulitis	targetBased	0.375440031217794	6	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diverticulitis	targetBased	0.375440031217794	6	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diverticulitis	targetBased	0.375440031217794	6	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	diverticulitis	targetBased	0.375440031217794	6	196177	519
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	peptic ulcer disease	targetBased	0.619285523949174	12	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	peptic ulcer disease	targetBased	0.619285523949174	12	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	peptic ulcer disease	targetBased	0.619285523949174	12	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	peptic ulcer disease	targetBased	0.619285523949174	12	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	peptic ulcer disease	targetBased	0.619285523949174	12	359207	4555
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	peptic ulcer disease	targetBased	0.60466648961276	9	363803	1450
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	peptic ulcer disease	targetBased	0.60466648961276	9	363803	2629
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	peptic ulcer disease	targetBased	0.60466648961276	9	363803	502
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	peptic ulcer disease	targetBased	0.60466648961276	9	363803	698
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	peptic ulcer disease	targetBased	0.60466648961276	9	363803	2133
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	peptic ulcer disease	targetBased	0.60466648961276	9	363803	1081
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	bowel dysfunction	targetBased	0.479330316738609	19	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	bowel dysfunction	targetBased	0.479330316738609	19	335239	695
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	colonic disorder	targetBased	0.131520063534352	33	336894	489
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	colonic disorder	targetBased	0.171854369131705	109	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	colonic disorder	targetBased	0.171854369131705	109	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	colonic disorder	targetBased	0.263358302353305	84	217959	2390
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	colonic disorder	pathwayBased	0.166154154319815	1129	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	colonic disorder	pathwayBased	0.166154154319815	1129	359244	3094
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	colonic disorder	targetBased	0.151048916654347	822	67275	2509
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	colonic disorder	targetBased	0.136528383743459	58	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	colonic disorder	pathwayBased	0.136528383743459	58	403871	1243
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colonic disorder	targetBased	0.282976593337145	320	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colonic disorder	targetBased	0.282976593337145	320	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colonic disorder	targetBased	0.282976593337145	320	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colonic disorder	targetBased	0.282976593337145	320	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colonic disorder	targetBased	0.282976593337145	320	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	colonic disorder	targetBased	0.282976593337145	320	196177	519
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	colonic disorder	targetBased	0.104157290114041	52	86095	1114
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	colonic disorder	targetBased	0.188079542433228	292	356517	1139
HTS of Smad transcription factor inhibitors	SMAD3	colonic disorder	targetBased	0.234442030805364	43	88033	251
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	colonic disorder	targetBased	0.276202125406148	222	292323	1836
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	colonic disorder	pathwayBased	0.198003595684103	127	43989	342
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	intestinal obstruction	targetBased	0.411120019776223	6	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	intestinal obstruction	targetBased	0.634364034199603	37	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	intestinal obstruction	targetBased	0.634364034199603	37	335239	695
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	intestinal obstruction	targetBased	0.406696647852918	5	316642	617
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	ileus	targetBased	0.426198928396305	5	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	ileus	targetBased	0.624516078630663	44	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	ileus	targetBased	0.624516078630663	44	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	short bowel syndrome	targetBased	0.427965459731281	9	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	short bowel syndrome	targetBased	0.427965459731281	9	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	short bowel syndrome	targetBased	0.427965459731281	9	405130	6428
qHTS assay for re-activators of p53 using a Luc reporter	TP53	small intestine disorder	pathwayBased	0.201464271300111	92	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	small intestine disorder	targetBased	0.201464271300111	92	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	small intestine disorder	targetBased	0.201464271300111	92	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	small intestine disorder	targetBased	0.201464271300111	92	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	small intestine disorder	targetBased	0.201464271300111	92	124022	1156
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	small intestine disorder	targetBased	0.137631854483729	5	316642	617
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	enteritis	targetBased	0.101338531490936	17	292323	1836
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	ulcer disease	targetBased	0.401332681215866	9	292323	1836
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	salivary gland neoplasm	pathwayBased	0.139823724490481	6	376029	3978
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	salivary gland neoplasm	targetBased	0.127450360507124	5	57013	201
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	salivary gland neoplasm	targetBased	0.102240315993491	9	356517	1139
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	salivary gland neoplasm	targetBased	0.19671703072317	11	193542	587
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	salivary gland neoplasm	pathwayBased	0.131101168001345	11	43989	342
qHTS assay for re-activators of p53 using a Luc reporter	TP53	parotid disease	pathwayBased	0.151426468445126	9	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	parotid disease	targetBased	0.151426468445126	9	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	parotid disease	targetBased	0.151426468445126	9	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	parotid disease	targetBased	0.151426468445126	9	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	parotid disease	targetBased	0.151426468445126	9	124022	1156
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	salivary gland disease	pathwayBased	0.139823724490481	6	376029	3978
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	salivary gland disease	targetBased	0.127495764920373	6	57013	201
qHTS assay for re-activators of p53 using a Luc reporter	TP53	salivary gland disease	pathwayBased	0.166045628587948	64	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	salivary gland disease	targetBased	0.166045628587948	64	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	salivary gland disease	targetBased	0.166045628587948	64	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	salivary gland disease	targetBased	0.166045628587948	64	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	salivary gland disease	targetBased	0.166045628587948	64	124022	1156
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	salivary gland disease	targetBased	0.144855569468029	4	322361	619
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	salivary gland disease	targetBased	0.19671703072317	11	193542	587
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	salivary gland disease	targetBased	0.223124685070182	18	194628	267
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	salivary gland disease	pathwayBased	0.131156363396237	13	43989	342
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	salivary gland disease	targetBased	0.183738498677122	8	343468	734
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	salivary gland disease	targetBased	0.102481516064321	12	356517	1139
HTS for developing T Cell Immune Modulators	ITGAL	intestinal disease	targetBased	0.101430783306978	16	326271	221
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).	PPP5C	intestinal disease	targetBased	0.12881045535508	4	314999	564
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	intestinal disease	pathwayBased	0.236565471108405	186	376029	3978
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	intestinal disease	pathwayBased	0.102508019793238	24	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	intestinal disease	pathwayBased	0.102508019793238	24	64908	278
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	intestinal disease	targetBased	0.10463613014089	11	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	intestinal disease	targetBased	0.10463613014089	11	359244	1307
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	intestinal disease	pathwayBased	0.151214947453312	9	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	intestinal disease	targetBased	0.159574796533532	53	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	intestinal disease	targetBased	0.121122860285039	35	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	intestinal disease	targetBased	0.121122860285039	35	290726	2649
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	intestinal disease	targetBased	0.179394964517329	14	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	intestinal disease	targetBased	0.102666967902203	6	359206	428
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	intestinal disease	targetBased	0.267351541529491	48	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	intestinal disease	targetBased	0.267351541529491	48	337446	1356
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	intestinal disease	targetBased	0.153711129775858	6	385746	932
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	intestinal disease	targetBased	0.159191597687086	10	194152	1342
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	intestinal disease	targetBased	0.261152368093564	182	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	intestinal disease	pathwayBased	0.170037717925935	41	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	intestinal disease	pathwayBased	0.170037717925935	41	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	intestinal disease	targetBased	0.139541898132279	11	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	intestinal disease	targetBased	0.207537686340734	29	46715	2829
Primary qHTS assay for inhibitors of human arachidonate 12S-lipoxygenase (ALOX12): Round 2	ALOX12_inhibitors	intestinal disease	targetBased	0.185608790570996	8	564288	6030
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	intestinal disease	targetBased	0.159367964020923	7	343468	285
qHTS of IL-2 Activators	IL2	intestinal disease	targetBased	0.120149762342543	420	364617	238
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	intestinal disease	targetBased	0.188741361625401	7	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	intestinal disease	targetBased	0.113191759955279	51	338328	2501
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	intestinal disease	targetBased	0.263136553708477	80	326888	645
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	intestinal disease	targetBased	0.1341553957767	36	75924	1804
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	intestinal disease	targetBased	0.15565362846769	45	325247	1021
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	intestinal disease	targetBased	0.193550533035486	16	369953	3123
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	intestinal disease	targetBased	0.104982309329976	20	353950	4145
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	intestinal disease	targetBased	0.198625686524713	23	217959	771
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	intestinal disease	targetBased	0.198625686524713	23	217959	569
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	intestinal disease	targetBased	0.185376160671588	6	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	intestinal disease	targetBased	0.21027293181987	34	344733	7043
USP8 deubiquitinase inhibition: Primary qHTS	USP8	intestinal disease	targetBased	0.154533719790588	8	47480	2010
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	intestinal disease	targetBased	0.155482904136805	6	368927	620
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	intestinal disease	pathwayBased	0.147071801746032	59	7671	874
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	intestinal disease	targetBased	0.147071801746032	59	304060	10600
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	intestinal disease	pathwayBased	0.147071801746032	59	305439	16717
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	intestinal disease	targetBased	0.205957757111476	16	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	intestinal disease	targetBased	0.205957757111476	16	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	intestinal disease	targetBased	0.205957757111476	16	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	intestinal disease	targetBased	0.205957757111476	16	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	intestinal disease	targetBased	0.205957757111476	16	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	intestinal disease	targetBased	0.205957757111476	16	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	intestinal disease	targetBased	0.287176355151255	100	322361	619
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	intestinal disease	targetBased	0.262685841878716	273	369953	3080
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	intestinal disease	targetBased	0.196755245992988	43	263421	615
E3 Ligase HTS_1536	MDM2	intestinal disease	targetBased	0.168947125242561	70	207811	220
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	intestinal disease	targetBased	0.162299840619863	8	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	intestinal disease	targetBased	0.162299840619863	8	194628	521
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	intestinal disease	targetBased	0.149041588345448	6	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	intestinal disease	targetBased	0.149041588345448	6	305610	3253
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	intestinal disease	targetBased	0.200559073805117	11	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	intestinal disease	targetBased	0.157213438775602	20	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	intestinal disease	targetBased	0.157213438775602	20	218234	1620
uHTS Luminescent assay for identification of inhibitors of human intestinal alkaline phosphatase	ALPI_inhibitors	intestinal disease	targetBased	0.184459425324749	22	330392	393
uHTS Luminescent assay for identification of inhibitors of mouse intestinal alkaline phosphatase	ALPI_inhibitors	intestinal disease	targetBased	0.184459425324749	22	331670	664
Luminescent assay for identification of activators of bovine intestinal alkaline phosphatase	ALPI_activators	intestinal disease	targetBased	0.184459425324749	22	195570	326
uHTS Luminescent assay for identification of activators of human intestinal alkaline phosphatase	ALPI_activators	intestinal disease	targetBased	0.184459425324749	22	330392	537
uHTS Luminescent assay for identification of activators of mouse intestinal alkaline phosphatase	ALPI_activators	intestinal disease	targetBased	0.184459425324749	22	331670	785
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	intestinal disease	targetBased	0.166010622733042	18	71016	346
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	intestinal disease	targetBased	0.156949732612937	37	148480	6428
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	intestinal disease	targetBased	0.144737410208928	12	335777	499
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	intestinal disease	targetBased	0.194833126217206	31	369953	2353
qHTS for Inhibitors of WRN Helicase	WRN	intestinal disease	targetBased	0.24895238630978	17	364011	1678
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	intestinal disease	targetBased	0.145316836034764	8	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	intestinal disease	targetBased	0.145316836034764	8	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	intestinal disease	targetBased	0.145316836034764	8	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	intestinal disease	targetBased	0.145316836034764	8	72026	1794
HTS of Smad transcription factor inhibitors	SMAD3	intestinal disease	targetBased	0.281779797644813	96	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	intestinal disease	targetBased	0.268586025959039	367	193542	587
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)	PAFAH1B2	intestinal disease	targetBased	0.105013711742327	5	335239	4158
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	intestinal disease	targetBased	0.104398377572245	12	386270	1331
OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	intestinal disease	targetBased	0.117665144667545	23	47480	334
Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity	MLLT3	intestinal disease	targetBased	0.102347892930117	4	344459	1627
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	intestinal disease	targetBased	0.109491079300376	5	31324	362
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	intestinal disease	targetBased	0.19635482496637	58	194628	267
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	intestinal disease	targetBased	0.196021147190473	9	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	intestinal disease	targetBased	0.196021147190473	9	61606	416
HCS assay for microtubule stabilizers	TUBB	intestinal disease	targetBased	0.138762726678409	27	195821	1625
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	intestinal disease	targetBased	0.101567813208114	4	104728	4230
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	intestinal disease	targetBased	0.208105293538328	14	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	intestinal disease	targetBased	0.181342263492155	11	331671	10022
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	intestinal disease	targetBased	0.12753951187052	141	343468	734
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	intestinal disease	targetBased	0.134030120785673	38	363803	1383
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	intestinal disease	targetBased	0.108033246220152	90	86095	1114
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	p47phoxInhibitors	intestinal disease	targetBased	0.104246077782217	19	217454	1142
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	intestinal disease	targetBased	0.215729122095815	81	55710	315
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	biliary tract disease	targetBased	0.174954934381303	35	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	biliary tract disease	targetBased	0.174954934381303	35	296501	2737
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	biliary tract disease	pathwayBased	0.205966892490357	36	376029	3978
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	biliary tract disease	targetBased	0.157007318292117	11	336894	489
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	biliary tract disease	targetBased	0.21967348408486	15	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	biliary tract disease	targetBased	0.21967348408486	15	337446	1356
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	biliary tract disease	targetBased	0.167444631881332	12	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	biliary tract disease	targetBased	0.136811743747336	8	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	biliary tract disease	pathwayBased	0.172662097836084	8	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	biliary tract disease	pathwayBased	0.172662097836084	8	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	biliary tract disease	targetBased	0.190422648896797	6	46715	2829
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	esophageal disease	pathwayBased	0.161486644810321	34	376029	3978
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	biliary tract disease	targetBased	0.180897290213134	43	57013	201
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	biliary tract disease	targetBased	0.121412241828512	5	343468	285
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	biliary tract disease	pathwayBased	0.164530274775241	105	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	biliary tract disease	pathwayBased	0.164530274775241	105	359244	3094
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	biliary tract disease	targetBased	0.104245002906551	14	338328	2501
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	biliary tract disease	targetBased	0.20202694721816	5	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	biliary tract disease	targetBased	0.20202694721816	5	335239	695
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	esophageal disease	pathwayBased	0.102580658913278	6	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	esophageal disease	targetBased	0.150321032541733	24	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	esophageal disease	targetBased	0.116999052702556	17	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	esophageal disease	targetBased	0.116999052702556	17	290726	2649
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	esophageal disease	targetBased	0.145034469060499	4	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	esophageal disease	targetBased	0.145034469060499	4	337446	1356
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	esophageal disease	targetBased	0.138614614299397	4	385746	932
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	esophageal disease	targetBased	0.206900623767966	52	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	esophageal disease	targetBased	0.206900623767966	52	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	esophageal disease	targetBased	0.165730732956527	31	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	esophageal disease	targetBased	0.167853003223802	11	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	esophageal disease	pathwayBased	0.167328604663591	17	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	esophageal disease	pathwayBased	0.167328604663591	17	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	esophageal disease	targetBased	0.139952719795136	9	46715	2829
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	esophageal disease	targetBased	0.156301703572436	50	57013	201
Primary qHTS assay for inhibitors of human arachidonate 12S-lipoxygenase (ALOX12): Round 2	ALOX12_inhibitors	esophageal disease	targetBased	0.177237887811495	6	564288	6030
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	esophageal disease	targetBased	0.101711451740033	38	338328	2501
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	esophageal disease	targetBased	0.168042672120834	9	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	esophageal disease	targetBased	0.219137549973724	58	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	esophageal disease	pathwayBased	0.219137549973724	58	403871	1243
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	esophageal disease	targetBased	0.135230274597126	4	369953	3123
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	esophageal disease	targetBased	0.134387167760908	8	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	esophageal disease	targetBased	0.216144931591686	19	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	esophageal disease	targetBased	0.137898774203478	35	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	esophageal disease	targetBased	0.137898774203478	35	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	esophageal disease	targetBased	0.137898774203478	35	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	esophageal disease	targetBased	0.137898774203478	35	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	esophageal disease	targetBased	0.137898774203478	35	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	esophageal disease	targetBased	0.137898774203478	35	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	esophageal disease	targetBased	0.119075651192838	8	263421	615
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	biliary tract disease	targetBased	0.168611236729175	4	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	biliary tract disease	targetBased	0.181608730458187	18	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	biliary tract disease	pathwayBased	0.181608730458187	18	403871	1243
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	biliary tract disease	targetBased	0.149830734675932	9	344733	7043
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	biliary tract disease	targetBased	0.122394134109876	69	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	biliary tract disease	targetBased	0.122394134109876	69	335180	1022
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	biliary tract disease	targetBased	0.18239531270955	27	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	biliary tract disease	targetBased	0.18239531270955	27	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	biliary tract disease	targetBased	0.18239531270955	27	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	biliary tract disease	targetBased	0.18239531270955	27	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	biliary tract disease	targetBased	0.18239531270955	27	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	biliary tract disease	targetBased	0.18239531270955	27	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	biliary tract disease	targetBased	0.137721130736681	5	263421	615
E3 Ligase HTS_1536	MDM2	biliary tract disease	targetBased	0.148974056748823	14	207811	220
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	biliary tract disease	targetBased	0.180117774027059	5	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	biliary tract disease	targetBased	0.180117774027059	5	194628	521
E3 Ligase HTS_1536	MDM2	esophageal disease	targetBased	0.166792459560453	68	207811	220
USP8 deubiquitinase inhibition: Primary qHTS	USP8	esophageal disease	targetBased	0.136683970652793	5	47480	2010
qHTS assay for re-activators of p53 using a Luc reporter	TP53	esophageal disease	pathwayBased	0.286509685530083	976	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal disease	targetBased	0.286509685530083	976	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal disease	targetBased	0.286509685530083	976	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal disease	targetBased	0.286509685530083	976	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	esophageal disease	targetBased	0.286509685530083	976	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	esophageal disease	targetBased	0.14439203425888	387	356517	1139
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	esophageal disease	targetBased	0.112949418858417	31	93798	679
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	esophageal disease	targetBased	0.21142960820566	7	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	esophageal disease	targetBased	0.21142960820566	7	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	esophageal disease	targetBased	0.21142960820566	7	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	esophageal disease	targetBased	0.21142960820566	7	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	esophageal disease	targetBased	0.21142960820566	7	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	esophageal disease	targetBased	0.21142960820566	7	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	esophageal disease	targetBased	0.175103949253225	42	322361	619
qHTS assay for re-activators of p53 using a Luc reporter	TP53	biliary tract disease	pathwayBased	0.262109813765427	352	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	biliary tract disease	targetBased	0.262109813765427	352	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	biliary tract disease	targetBased	0.262109813765427	352	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	biliary tract disease	targetBased	0.262109813765427	352	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	biliary tract disease	targetBased	0.262109813765427	352	124022	1156
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	biliary tract disease	targetBased	0.195725209998113	20	322361	619
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	biliary tract disease	targetBased	0.122531417380512	7	325630	216
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	biliary tract disease	targetBased	0.179014143479589	4	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	biliary tract disease	targetBased	0.141106864481345	11	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	biliary tract disease	targetBased	0.141106864481345	11	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	biliary tract disease	targetBased	0.236781323817186	19	71016	346
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	esophageal disease	targetBased	0.173560529730411	4	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	esophageal disease	targetBased	0.153695536467353	15	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	esophageal disease	targetBased	0.153695536467353	15	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	esophageal disease	targetBased	0.166506375767279	6	71016	346
uHTS for 14-3-3/Bad interaction inhibitors	YWHAZ	esophageal disease	targetBased	0.102570759914913	7	217332	1549
qHTS for Inhibitors of WRN Helicase	WRN	esophageal disease	targetBased	0.191754715622543	7	364011	1678
HTS of Smad transcription factor inhibitors	SMAD3	esophageal disease	targetBased	0.194916238556379	22	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	esophageal disease	targetBased	0.192213291090885	53	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	esophageal disease	pathwayBased	0.162360550737552	170	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	esophageal disease	pathwayBased	0.162360550737552	170	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	esophageal disease	targetBased	0.191600561848195	5	339297	1446
HTS of Smad transcription factor inhibitors	SMAD3	biliary tract disease	targetBased	0.207917987866813	8	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	biliary tract disease	targetBased	0.231001266551921	38	193542	587
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	esophageal disease	targetBased	0.171768506342496	12	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	esophageal disease	targetBased	0.135165226270177	7	218654	8241
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	biliary tract disease	pathwayBased	0.204528347323803	95	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	biliary tract disease	pathwayBased	0.204528347323803	95	194666	1722
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	biliary tract disease	targetBased	0.139045987937789	8	194628	267
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	biliary tract disease	targetBased	0.179871714145841	5	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	biliary tract disease	targetBased	0.179871714145841	5	331360	2760
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	esophageal disease	targetBased	0.19148661159607	5	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	esophageal disease	targetBased	0.19148661159607	5	331360	2760
HCS assay for microtubule stabilizers	TUBB	esophageal disease	targetBased	0.195319806594737	134	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	esophageal disease	targetBased	0.187878760757735	7	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	esophageal disease	targetBased	0.142872648633855	6	331671	10022
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	esophageal disease	pathwayBased	0.198632349484476	156	43989	342
HCS assay for microtubule stabilizers	TUBB	biliary tract disease	targetBased	0.135387301050889	20	195821	1625
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	biliary tract disease	targetBased	0.135766365463072	5	316642	617
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	biliary tract disease	targetBased	0.148693854192137	4	347933	673
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	biliary tract disease	pathwayBased	0.189230377457323	84	43989	342
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	disease of peritoneum	targetBased	0.143502261837141	4	344733	7043
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	disease of peritoneum	targetBased	0.131520183275296	12	322361	619
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	disease of peritoneum	targetBased	0.239715581954269	84	71016	346
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	disease of peritoneum	targetBased	0.143162950147737	6	193542	587
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	disorder of appendix	targetBased	0.168840003758333	8	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	disorder of appendix	targetBased	0.168840003758333	8	337446	1356
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	biliary tract disease	pathwayBased	0.132135322967985	4	358556	3721
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	biliary tract disease	targetBased	0.178777478994521	4	309684	1662
USP8 deubiquitinase inhibition: Primary qHTS	USP8	biliary tract disease	targetBased	0.174730860546456	7	47480	2010
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	biliary tract disease	targetBased	0.153287307285792	215	356517	1139
HCS assay for microtubule stabilizers	TUBB	disease of peritoneum	targetBased	0.193517983302583	81	195821	1625
qHTS assay for re-activators of p53 using a Luc reporter	TP53	disorder of appendix	pathwayBased	0.143104560131717	12	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disorder of appendix	targetBased	0.143104560131717	12	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disorder of appendix	targetBased	0.143104560131717	12	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disorder of appendix	targetBased	0.143104560131717	12	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	disorder of appendix	targetBased	0.143104560131717	12	124022	1156
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	disorder of appendix	targetBased	0.134712522928826	5	193542	587
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	stomach disease	pathwayBased	0.24963796132147	37	376029	3978
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	stomach disease	targetBased	0.118265588402072	9	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	stomach disease	targetBased	0.118265588402072	9	290726	2649
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	stomach disease	targetBased	0.232891928579322	19	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	stomach disease	targetBased	0.232891928579322	19	337446	1356
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	stomach disease	targetBased	0.169316445076582	13	217959	2390
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	stomach disease	pathwayBased	0.157745433073832	10	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	stomach disease	pathwayBased	0.157745433073832	10	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	stomach disease	targetBased	0.178472726512756	4	46715	2829
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	stomach disease	targetBased	0.176628715733264	4	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	stomach disease	targetBased	0.101027082506027	18	338328	2501
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	stomach disease	targetBased	0.183415657748161	7	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	stomach disease	targetBased	0.147472481844127	14	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	stomach disease	pathwayBased	0.147472481844127	14	403871	1243
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	stomach disease	targetBased	0.195970305700043	11	369953	3123
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	stomach disease	targetBased	0.100798033713982	8	353950	4145
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	stomach disease	targetBased	0.129533965903405	5	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	stomach disease	targetBased	0.206663300832383	12	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	stomach disease	targetBased	0.146910492794997	30	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	stomach disease	targetBased	0.146910492794997	30	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	stomach disease	targetBased	0.146910492794997	30	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	stomach disease	targetBased	0.146910492794997	30	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	stomach disease	targetBased	0.146910492794997	30	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	stomach disease	targetBased	0.146910492794997	30	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	stomach disease	targetBased	0.149048734001694	16	263421	615
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	stomach disease	targetBased	0.103354433927447	10	93798	679
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	stomach disease	targetBased	0.222727013425377	23	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	stomach disease	targetBased	0.222727013425377	23	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	stomach disease	targetBased	0.222727013425377	23	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	stomach disease	targetBased	0.222727013425377	23	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	stomach disease	targetBased	0.222727013425377	23	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	stomach disease	targetBased	0.222727013425377	23	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	stomach disease	targetBased	0.270257833247462	75	322361	619
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	stomach disease	targetBased	0.200094570283736	6	335531	328
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	rectal disease	pathwayBased	0.101557190330656	5	376029	3978
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	rectal disease	targetBased	0.180921546531868	5	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	rectal disease	targetBased	0.180921546531868	5	337446	1356
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	rectal disease	targetBased	0.136875731133718	7	359207	1432
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rectal disease	targetBased	0.21158097143505	5	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rectal disease	targetBased	0.21158097143505	5	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rectal disease	targetBased	0.21158097143505	5	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rectal disease	targetBased	0.21158097143505	5	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rectal disease	targetBased	0.21158097143505	5	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	rectal disease	targetBased	0.21158097143505	5	196177	519
E3 Ligase HTS_1536	MDM2	rectal disease	targetBased	0.101856600228584	4	207811	220
qHTS assay for re-activators of p53 using a Luc reporter	TP53	rectal disease	pathwayBased	0.229811136836429	96	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	rectal disease	targetBased	0.229811136836429	96	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	rectal disease	targetBased	0.229811136836429	96	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	rectal disease	targetBased	0.229811136836429	96	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	rectal disease	targetBased	0.229811136836429	96	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	rectal disease	targetBased	0.108339187697906	10	356517	1139
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	stomach disease	targetBased	0.143350120382454	4	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	stomach disease	targetBased	0.143350120382454	4	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	stomach disease	targetBased	0.206902840904954	6	71016	346
qHTS for Inhibitors of WRN Helicase	WRN	stomach disease	targetBased	0.203454333259954	6	364011	1678
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	stomach disease	targetBased	0.107093572753146	4	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	stomach disease	targetBased	0.107093572753146	4	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	stomach disease	targetBased	0.107093572753146	4	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	stomach disease	targetBased	0.107093572753146	4	72026	1794
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	stomach disease	targetBased	0.242010389540166	63	193542	587
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	stomach disease	targetBased	0.100998221732829	8	318291	483
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	stomach disease	targetBased	0.186609516030956	22	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	stomach disease	targetBased	0.127030318611918	5	218654	8241
HCS assay for microtubule stabilizers	TUBB	stomach disease	targetBased	0.209951398343354	180	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	stomach disease	targetBased	0.164281296415801	6	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	stomach disease	targetBased	0.204655561355192	10	331671	10022
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	rectal disease	targetBased	0.118916490657654	6	322361	619
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	rectal disease	targetBased	0.166896834163947	9	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	rectal disease	pathwayBased	0.101935018817883	4	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	rectal disease	pathwayBased	0.101935018817883	4	194666	1722
HCS assay for microtubule stabilizers	TUBB	rectal disease	targetBased	0.107451196092493	4	195821	1625
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	rectal disease	pathwayBased	0.127933192574665	9	43989	342
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	anus disease	targetBased	0.195270739656322	4	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	anus disease	targetBased	0.195270739656322	4	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	anus disease	targetBased	0.195270739656322	4	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	anus disease	targetBased	0.195270739656322	4	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	anus disease	targetBased	0.195270739656322	4	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	anus disease	targetBased	0.195270739656322	4	196177	519
qHTS assay for re-activators of p53 using a Luc reporter	TP53	anus disease	pathwayBased	0.163554881450315	21	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	anus disease	targetBased	0.163554881450315	21	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	anus disease	targetBased	0.163554881450315	21	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	anus disease	targetBased	0.163554881450315	21	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	anus disease	targetBased	0.163554881450315	21	124022	1156
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	anus disease	pathwayBased	0.102559239991565	6	43989	342
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	malabsorption syndrome	pathwayBased	0.305064373065845	280	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	malabsorption syndrome	targetBased	0.305064373065845	280	195980	695
HTS for developing T Cell Immune Modulators	ITGAL	gastrointestinal disease	targetBased	0.104493469637468	56	326271	221
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).	PPP5C	gastrointestinal disease	targetBased	0.152766062605734	11	314999	564
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	gastrointestinal disease	pathwayBased	0.292809800146558	674	376029	3978
Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels	KCNQ1	gastrointestinal disease	targetBased	0.223133199776835	279	305610	3878
Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels	KCNQ1	gastrointestinal disease	targetBased	0.223133199776835	279	305610	1082
Primary Cell-based High Throughput Screening assay for activators of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	gastrointestinal disease	pathwayBased	0.141306956955236	118	64908	979
Primary Cell-based High Throughput Screening assay for inhibitors of the Retinoic Acid Receptor-related orphan receptor A (RORA)	RORA	gastrointestinal disease	pathwayBased	0.141306956955236	118	64908	278
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	gastrointestinal disease	targetBased	0.16648648861363	52	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	gastrointestinal disease	targetBased	0.16648648861363	52	359244	1307
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	gastrointestinal disease	pathwayBased	0.166880618779784	45	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	gastrointestinal disease	targetBased	0.204634590094032	358	336894	489
Luminescence-based cell-based primary high throughput screening assay to identify activators of the function of SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2 (SMARCA2, BRM)	SMARCA2	gastrointestinal disease	targetBased	0.150268944160655	37	368927	3838
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	gastrointestinal disease	targetBased	0.143751901397482	185	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	gastrointestinal disease	targetBased	0.143751901397482	185	290726	2649
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	gastrointestinal disease	targetBased	0.119606679969425	31	359206	428
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS4-Galphao.	GNAO1	gastrointestinal disease	targetBased	0.108316291732967	27	218528	711
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS7-Galphao.	GNAO1	gastrointestinal disease	targetBased	0.108316291732967	27	218528	770
Multiplexed high-throughput screen for small molecule regulators of RGS family protein interactions, specifically RGS8-Galphao.	GNAO1	gastrointestinal disease	targetBased	0.108316291732967	27	218528	750
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	gastrointestinal disease	targetBased	0.167755241729264	43	385746	932
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	gastrointestinal disease	targetBased	0.162741142338214	37	194152	1342
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	gastrointestinal disease	targetBased	0.285204436351899	532	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	gastrointestinal disease	targetBased	0.26976163988946	302	359207	1432
uHTS identification of modulators of interaction between CendR and NRP-1 using Fluorescence Polarization assay	NRP1	gastrointestinal disease	targetBased	0.101245906208585	118	363840	3086
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	gastrointestinal disease	pathwayBased	0.253949704640608	284	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	gastrointestinal disease	pathwayBased	0.253949704640608	284	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	gastrointestinal disease	targetBased	0.19450731319173	44	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	gastrointestinal disease	targetBased	0.229814187624333	129	46715	2829
qHTS Assay for Inhibitors of the CtBP/E1A Interaction	RBBP8	gastrointestinal disease	targetBased	0.209827344915293	12	335214	1652
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	gastrointestinal disease	targetBased	0.208282586861204	38	363803	2412
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	gastrointestinal disease	targetBased	0.173454869391265	119	290726	671
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	gastrointestinal disease	targetBased	0.229634748916525	672	57013	201
Primary qHTS assay for inhibitors of human arachidonate 12S-lipoxygenase (ALOX12): Round 2	ALOX12_inhibitors	gastrointestinal disease	targetBased	0.206531906123968	66	564288	6030
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	gastrointestinal disease	targetBased	0.244323770856061	55	343468	285
qHTS of IL-2 Activators	IL2	gastrointestinal disease	targetBased	0.13316638131151	1520	364617	238
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	gastrointestinal disease	targetBased	0.225860725229992	42	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	gastrointestinal disease	targetBased	0.119412984483291	302	338328	2501
uHTS identification of small molecule antagonists of the CCR6 receptor via a luminescent beta-arrestin assay	CCR6_antagonists	gastrointestinal disease	targetBased	0.128176815139925	15	340696	1654
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	gastrointestinal disease	targetBased	0.27152326731022	115	326888	645
Small-molecule inhibitors of ST2 (IL1RL1)	IL1RL1	gastrointestinal disease	targetBased	0.139330824393564	54	75924	1804
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	gastrointestinal disease	targetBased	0.255795785917352	248	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	gastrointestinal disease	targetBased	0.283252811812483	688	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	gastrointestinal disease	pathwayBased	0.283252811812483	688	403871	1243
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	gastrointestinal disease	targetBased	0.208056487509995	100	363803	458
Fluorescence polarization-based cell-based primary high throughput screening assay to identify activators of insulin-degrading enzyme (IDE)	IDE	gastrointestinal disease	targetBased	0.121023946732718	118	335239	245
Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE)	IDE	gastrointestinal disease	targetBased	0.121023946732718	118	324747	1316
uHTS Fluorescent assay for identification of activators of Apaf-1	APAF1_activators	gastrointestinal disease	targetBased	0.10102337635462	44	331671	1041
uHTS Fluorescent assay for identification of inhibitors of Apaf-1	APAF1_inhibitors	gastrointestinal disease	targetBased	0.10102337635462	44	331671	2353
uHTS identification of Caspase-8 TRAIL sensitizers in a luminesence assay	TNFRSF10B	gastrointestinal disease	targetBased	0.114523641022307	170	363840	3764
qHTS for Inhibitors of Cell Surface uPA Generation	PLAU	gastrointestinal disease	targetBased	0.161241965928027	230	325247	1021
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	gastrointestinal disease	targetBased	0.234158701179551	70	369953	3123
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	gastrointestinal disease	targetBased	0.117603972579397	93	353950	4145
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	gastrointestinal disease	targetBased	0.209134318621081	32	217959	771
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	gastrointestinal disease	targetBased	0.209134318621081	32	217959	569
Primary biochemical fluorescence polarization-based high throughput screening assay to identify inhibitors of protein arginine methyltransferase 1 (PRMT1)	PRMT1	gastrointestinal disease	targetBased	0.100484571463705	70	369953	4757
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	gastrointestinal disease	targetBased	0.215728024431536	61	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	gastrointestinal disease	targetBased	0.270614413856281	159	344733	7043
qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore)	GNAI1	gastrointestinal disease	targetBased	0.10404766432437	30	229888	1007
Luminescence Cell-Based Primary HTS to Identify Inhibitors of STK33	STK33	gastrointestinal disease	targetBased	0.106509542192313	16	37341	2812
Luminescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine Kinase 33 Activity	STK33	gastrointestinal disease	targetBased	0.106509542192313	16	321808	235
Factor XIIa 1536 HTS	F12_modulation	gastrointestinal disease	targetBased	0.144260437454582	23	217430	649
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	gastrointestinal disease	targetBased	0.139634507373663	360	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	gastrointestinal disease	targetBased	0.139634507373663	360	335180	1022
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	gastrointestinal disease	targetBased	0.288926026114239	411	263421	615
E3 Ligase HTS_1536	MDM2	gastrointestinal disease	targetBased	0.248094120744802	452	207811	220
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	gastrointestinal disease	targetBased	0.228659996214282	41	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	gastrointestinal disease	targetBased	0.228659996214282	41	194628	521
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	gastrointestinal disease	targetBased	0.171704020572574	84	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	gastrointestinal disease	targetBased	0.171704020572574	84	305610	3253
USP8 deubiquitinase inhibition: Primary qHTS	USP8	gastrointestinal disease	targetBased	0.228470060484291	38	47480	2010
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	gastrointestinal disease	targetBased	0.207686559401033	235	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	gastrointestinal disease	targetBased	0.239523363654346	23	368927	620
qHTS Assay for NPC1 Promoter Activators	NPC1	gastrointestinal disease	pathwayBased	0.134120682573982	53	320682	7575
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	gastrointestinal disease	targetBased	0.157911646074333	47	108286	1415
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	gastrointestinal disease	pathwayBased	0.157733198515103	104	7671	874
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	gastrointestinal disease	targetBased	0.157733198515103	104	304060	10600
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	gastrointestinal disease	pathwayBased	0.157733198515103	104	305439	16717
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	gastrointestinal disease	targetBased	0.11895388380973	221	93798	679
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	gastrointestinal disease	targetBased	0.313769186613035	558	322361	619
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-beta3).	PLCB3	gastrointestinal disease	targetBased	0.105947328348397	12	369953	662
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	gastrointestinal disease	targetBased	0.148200568497349	66	276265	806
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	gastrointestinal disease	targetBased	0.22586173169961	18	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	gastrointestinal disease	targetBased	0.22586173169961	18	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	gastrointestinal disease	targetBased	0.22586173169961	18	407539	2380
QFRET-based biochemical primary high throughput screening assay to identify exosite inhibitors of ADAM17.	ADAM17_inhibitors	gastrointestinal disease	targetBased	0.263599855350939	432	369953	3080
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	gastrointestinal disease	targetBased	0.192004778299403	143	325630	216
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	gastrointestinal disease	targetBased	0.163958011078626	37	340696	540
uHTS of small molecular inhibitors for p47phox, a regulatory protein of NADPH oxidases (Noxs)	p47phoxInhibitors	gastrointestinal disease	targetBased	0.117476139296129	73	217454	1142
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	gastrointestinal disease	targetBased	0.221403550207962	134	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	gastrointestinal disease	targetBased	0.221403550207962	134	218234	1620
qHTS for PTHR1 Agonists: Primary Screen	PTH1R	gastrointestinal disease	targetBased	0.117243469330359	17	405685	308
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	gastrointestinal disease	targetBased	0.287120827849473	163	71016	346
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	gastrointestinal disease	targetBased	0.162149690155714	71	148480	6428
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	gastrointestinal disease	targetBased	0.168938956280752	33	335777	499
Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of human diacylglycerol lipase, beta (DAGLB)	DAGLB_inhibitors	gastrointestinal disease	targetBased	0.137754738715669	5	343468	202
uHTS for 14-3-3/Bad interaction inhibitors	YWHAZ	gastrointestinal disease	targetBased	0.118646632056597	71	217332	1549
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	gastrointestinal disease	targetBased	0.217645116160563	51	369953	2353
qHTS for Inhibitors of WRN Helicase	WRN	gastrointestinal disease	targetBased	0.284615917758805	58	364011	1678
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	gastrointestinal disease	targetBased	0.185913171224615	44	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	gastrointestinal disease	targetBased	0.185913171224615	44	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	gastrointestinal disease	targetBased	0.185913171224615	44	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	gastrointestinal disease	targetBased	0.185913171224615	44	72026	1794
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	gastrointestinal disease	targetBased	0.211336087890814	15	324747	813
Luminescence-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): agonists of MC4R	MC4R	gastrointestinal disease	targetBased	0.219902537409309	261	356160	3470
TRFRET-based cell-based primary high throughput screening assay to identify biased ligands of the melanocortin 4 receptor (MC4R): antagonists of MC4R	MC4R	gastrointestinal disease	targetBased	0.219902537409309	261	356160	1703
HTS of Smad transcription factor inhibitors	SMAD3	gastrointestinal disease	targetBased	0.2981091823051	433	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	gastrointestinal disease	targetBased	0.31768133228557	1458	193542	587
Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of human platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 (PAFAH1B2)	PAFAH1B2	gastrointestinal disease	targetBased	0.121417616781695	16	335239	4158
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	gastrointestinal disease	targetBased	0.120864842358742	58	386270	1331
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	gastrointestinal disease	targetBased	0.190921641975683	14	305610	3794
OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	gastrointestinal disease	targetBased	0.136463448283477	33	47480	334
HTS for 14-3-3 protein interaction modulators	YWHAG	gastrointestinal disease	targetBased	0.104766970349099	13	157962	312
qHTS Assay for Activators of Human alpha-Glucosidase as a Potential Chaperone Treatment of Pompe Disease	GAA	gastrointestinal disease	targetBased	0.21462068957783	57	199169	715
qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase Cleavage of Glycogen	GAA_inhibitors	gastrointestinal disease	targetBased	0.21462068957783	57	302297	1165
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK3	KCNK3	gastrointestinal disease	targetBased	0.184873422701528	11	339674	2841
Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3	HDAC3	gastrointestinal disease	targetBased	0.10751628289169	182	318291	483
Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity	MLLT3	gastrointestinal disease	targetBased	0.130180356805543	20	344459	1627
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	gastrointestinal disease	targetBased	0.16367620589902	19	31324	362
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Agonists.	TRHR	gastrointestinal disease	targetBased	0.144569987528856	4	361330	651
qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Primary Screen for Enhancers	TRHR	gastrointestinal disease	targetBased	0.144569987528856	4	361330	2424
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	gastrointestinal disease	targetBased	0.265204098812013	327	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	gastrointestinal disease	targetBased	0.172930043009415	378	218654	8241
Absorbance-based biochemical primary high throughput screening assay to identify activators of Methionine sulfoxide reductase A (MsrA)	MSRA	gastrointestinal disease	targetBased	0.165631221932114	8	362026	1074
Absorbance-based biochemical primary high throughput screening assay to identify inhibitors of Methionine sulfoxide reductase A (MsrA)	MSRA	gastrointestinal disease	targetBased	0.165631221932114	8	362577	2709
Glucocerebrosidase	GBA1	gastrointestinal disease	targetBased	0.106079421835122	74	48118	549
uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay	UBE2N	gastrointestinal disease	targetBased	0.10313700521933	13	330393	1538
Assay for HTS of Gi/Go-linked GPCRs using mGluR8: Primary Screening	GRM8	gastrointestinal disease	targetBased	0.151908351849933	7	105151	2166
Thrombin 1536 HTS	F2_modulation	gastrointestinal disease	targetBased	0.186037512198385	694	217233	557
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	gastrointestinal disease	targetBased	0.260881738372858	91	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	gastrointestinal disease	targetBased	0.260881738372858	91	331360	2760
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	gastrointestinal disease	targetBased	0.259300711784485	44	347933	673
Alphascreen assay for small molecules abrogating mHTT-CaM Interaction	HTT	gastrointestinal disease	targetBased	0.111384780455362	18	189882	6790
Primary qHTS for Identification of Small Molecule Inhibitors of Huntingtin Promoter Activity	HTT	gastrointestinal disease	targetBased	0.111384780455362	18	48068	449
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP)	HTT	gastrointestinal disease	targetBased	0.111384780455362	18	220571	2380
qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP)	HTT	gastrointestinal disease	targetBased	0.111384780455362	18	223611	305
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	gastrointestinal disease	targetBased	0.25817151429536	56	331671	10022
uHTS identification of small molecule modulators of NR3A	GRIN3A	gastrointestinal disease	targetBased	0.213648626685929	11	339772	8480
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	gastrointestinal disease	pathwayBased	0.27437888372023	2809	43989	342
Primary qHTS for Inhibitors of ATXN expression	ATXN2_repressors	gastrointestinal disease	targetBased	0.135047408448522	55	358434	2554
Primary HTS Assay for S1P3 Antagonists	S1PR3	gastrointestinal disease	targetBased	0.154644535758242	19	169141	462
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	gastrointestinal disease	targetBased	0.227657848733391	528	343468	734
Primary screen for compounds that activate Insulin promoter activity in TRM-6 cells	INS	gastrointestinal disease	targetBased	0.320960159387738	2595	128695	1039
Primary screen for compounds that inhibit Insulin promoter activity in TRM-6 cells	INS	gastrointestinal disease	targetBased	0.320960159387738	2595	127961	1153
Primary Cell-Based High-Throughput Screening to Identify Agonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	gastrointestinal disease	targetBased	0.160793537164115	78	96879	447
Primary Cell-Based High-Throughput Screening to Identify Antagonists of the Sphingosine 1-phosphate receptor 2 (S1P2)	S1PR2	gastrointestinal disease	targetBased	0.160793537164115	78	96879	207
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	hepatobiliary disease	pathwayBased	0.233299171288249	100	376029	3978
uHTS fluorescence polarization assay for the identification of translation initiation inhibitors (PABP)	PABPC1	hepatobiliary disease	targetBased	0.163197725468031	20	290915	2982
uHTS identification of microRNA-mediated mRNA deadenylation inhibitors by fluoresence polarization assay	PABPC1	hepatobiliary disease	targetBased	0.163197725468031	20	359244	1307
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	hepatobiliary disease	pathwayBased	0.154245443760798	17	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	hepatobiliary disease	targetBased	0.192831865392446	168	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	hepatobiliary disease	targetBased	0.111967832806084	69	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	hepatobiliary disease	targetBased	0.111967832806084	69	290726	2649
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	hepatobiliary disease	targetBased	0.153521442408727	11	290355	265
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 1 (SRC1; NCOA1)	NCOA1	hepatobiliary disease	targetBased	0.110597314863047	10	359206	428
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	hepatobiliary disease	targetBased	0.155249960083543	21	385746	932
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	hepatobiliary disease	targetBased	0.105079423077969	14	194152	1342
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	hepatobiliary disease	targetBased	0.243335422522965	352	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	hepatobiliary disease	targetBased	0.243335422522965	352	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	hepatobiliary disease	targetBased	0.203893104985258	193	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	hepatobiliary disease	targetBased	0.186799141278052	55	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	hepatobiliary disease	pathwayBased	0.211260909234671	110	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	hepatobiliary disease	pathwayBased	0.211260909234671	110	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	hepatobiliary disease	targetBased	0.128684420801562	16	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	hepatobiliary disease	targetBased	0.207500951071491	51	46715	2829
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	hepatobiliary disease	targetBased	0.163530826036249	14	363803	2412
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	hepatobiliary disease	targetBased	0.195647925547466	371	57013	201
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	hepatobiliary disease	targetBased	0.15033107261082	11	343468	285
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	hepatobiliary disease	pathwayBased	0.173550674308779	1849	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	hepatobiliary disease	pathwayBased	0.173550674308779	1849	359244	3094
qHTS of IL-2 Activators	IL2	hepatobiliary disease	targetBased	0.117045934599004	444	364617	238
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	hepatobiliary disease	targetBased	0.208124287636066	12	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	hepatobiliary disease	targetBased	0.113792748592726	97	338328	2501
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	hepatobiliary disease	targetBased	0.228746590466616	163	394050	3624
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	hepatobiliary disease	targetBased	0.101140056534914	1542	67275	2509
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	hepatobiliary disease	targetBased	0.215871940867625	24	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	hepatobiliary disease	targetBased	0.215871940867625	24	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	hepatobiliary disease	targetBased	0.204483646617692	401	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	hepatobiliary disease	targetBased	0.204483646617692	401	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	hepatobiliary disease	targetBased	0.204483646617692	401	405130	6428
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	hepatobiliary disease	targetBased	0.208029096495953	129	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	hepatobiliary disease	targetBased	0.266173945715519	278	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	hepatobiliary disease	pathwayBased	0.266173945715519	278	403871	1243
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	hepatobiliary disease	targetBased	0.122376234550443	27	363803	458
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	hepatobiliary disease	targetBased	0.160353525938876	21	369953	3123
HTS for PAX8 inhibitors using PAX8 luciferase reporter gene assay in RMG-I cells Measured in Cell-Based System Using Plate Reader - 7054-01_Inhibitor_SinglePoint_HTS_Activity	PAX8	hepatobiliary disease	targetBased	0.108541418108503	18	353950	4145
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	hepatobiliary disease	targetBased	0.190711597413071	33	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	hepatobiliary disease	targetBased	0.212328713611818	58	344733	7043
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	hepatobiliary disease	targetBased	0.122786576361256	85	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	hepatobiliary disease	targetBased	0.122786576361256	85	335180	1022
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	hepatobiliary disease	targetBased	0.167329973608451	21	263421	615
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	hepatobiliary disease	targetBased	0.207821447045824	16	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	hepatobiliary disease	targetBased	0.207821447045824	16	194628	521
USP8 deubiquitinase inhibition: Primary qHTS	USP8	hepatobiliary disease	targetBased	0.213297210219203	15	47480	2010
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	hepatobiliary disease	targetBased	0.191533238653504	47	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	hepatobiliary disease	targetBased	0.205775427659954	8	368927	620
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	hepatobiliary disease	targetBased	0.135711779783981	6	108286	1415
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	hepatobiliary disease	targetBased	0.140703132158959	11	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	hepatobiliary disease	targetBased	0.140703132158959	11	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	hepatobiliary disease	targetBased	0.140703132158959	11	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	hepatobiliary disease	targetBased	0.140703132158959	11	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	hepatobiliary disease	targetBased	0.140703132158959	11	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	hepatobiliary disease	targetBased	0.140703132158959	11	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	hepatobiliary disease	targetBased	0.24126381887999	100	322361	619
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	hepatobiliary disease	targetBased	0.130003212633344	61	325630	216
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	hepatobiliary disease	targetBased	0.243264311857587	9	335531	328
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	hepatobiliary disease	targetBased	0.18805189787513	6	369953	2353
qHTS for Inhibitors of WRN Helicase	WRN	hepatobiliary disease	targetBased	0.194949916299053	6	364011	1678
Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	hepatobiliary disease	targetBased	0.104539783439416	13	329153	670
Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign	TSHR	hepatobiliary disease	targetBased	0.104539783439416	13	329153	670
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor	TSHR	hepatobiliary disease	targetBased	0.104539783439416	13	72026	352
qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293	TSHR	hepatobiliary disease	targetBased	0.104539783439416	13	72026	1794
HTS of Smad transcription factor inhibitors	SMAD3	hepatobiliary disease	targetBased	0.232536282971102	173	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	hepatobiliary disease	targetBased	0.304072292572626	779	193542	587
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	hepatobiliary disease	targetBased	0.109055770299879	28	386270	1331
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	hepatobiliary disease	pathwayBased	0.230074143610555	1252	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	hepatobiliary disease	pathwayBased	0.230074143610555	1252	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	hepatobiliary disease	targetBased	0.218722620378742	30	339297	1446
Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9	KCNK9_blockers	hepatobiliary disease	targetBased	0.173225499220873	4	305610	3794
Inhibition of the MLL-AF4-AF9 Interaction in Pediatric Leukemia Measured in Biochemical System Using Plate Reader - 2160-01_Inhibitor_SinglePoint_HTS_Activity	MLLT3	hepatobiliary disease	targetBased	0.101919235435679	6	344459	1627
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	hepatobiliary disease	targetBased	0.190911839025298	148	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	hepatobiliary disease	targetBased	0.151844513368892	159	218654	8241
Glucocerebrosidase	GBA1	hepatobiliary disease	targetBased	0.104183798486477	41	48118	549
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	hepatobiliary disease	targetBased	0.21282684832897	25	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	hepatobiliary disease	targetBased	0.21282684832897	25	331360	2760
HCS assay for microtubule stabilizers	TUBB	hepatobiliary disease	targetBased	0.201138703475521	35	195821	1625
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	hepatobiliary disease	targetBased	0.206853606983743	33	316642	617
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	hepatobiliary disease	targetBased	0.195082888658765	8	347933	673
uHTS identification of small molecule modulators of NR3A	GRIN3A	hepatobiliary disease	targetBased	0.196225566665494	6	339772	8480
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	hepatobiliary disease	pathwayBased	0.219338540178192	1351	43989	342
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	hepatobiliary disease	targetBased	0.216728630177879	233	343468	734
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of the interaction of nucleotide-binding oligomerization domain containing 2 (NOD2) and the receptor-interacting serine-threonine kinase 2 (RIPK2)	RIPK2	gastrointestinal disease	targetBased	0.156703055623001	60	363803	1383
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	gastrointestinal disease	targetBased	0.231220365627381	140	55710	315
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	hepatobiliary disease	targetBased	0.252559439624571	49	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	hepatobiliary disease	targetBased	0.252559439624571	49	337446	1356
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	hepatobiliary disease	targetBased	0.182662456937424	2775	356517	1139
Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2	THRB	hepatobiliary disease	targetBased	0.137568768069957	49	276265	806
uHTS Fluorescent assay for identification of inhibitors of hexokinase domain containing I (HKDC1)	HKDC1	hepatobiliary disease	targetBased	0.160741937145607	18	340696	540
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	hepatobiliary disease	targetBased	0.198801193486026	56	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	hepatobiliary disease	targetBased	0.198801193486026	56	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	hepatobiliary disease	targetBased	0.249782482673105	31	71016	346
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	hepatobiliary disease	targetBased	0.105087811810551	617	326024	350
MLPCN ERAP1 Measured in Biochemical System Using Plate Reader - 7016-01_Inhibitor_SinglePoint_HTS_Activity	ERAP1_inhibitors	hepatobiliary disease	targetBased	0.11912117153766	7	335777	499
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	hepatobiliary disease	targetBased	0.207881041819684	11	324747	813
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	hepatobiliary disease	targetBased	0.205839360705494	18	331671	10022
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	mouth disease	pathwayBased	0.152611065952	16	376029	3978
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	mouth disease	pathwayBased	0.122478854644805	6	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	mouth disease	targetBased	0.140515721820692	16	336894	489
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	mouth disease	targetBased	0.141860656424844	7	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	mouth disease	targetBased	0.141860656424844	7	337446	1356
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	mouth disease	targetBased	0.137043999214659	32	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	mouth disease	targetBased	0.155635908071394	6	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	mouth disease	pathwayBased	0.135934069051813	13	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	mouth disease	pathwayBased	0.135934069051813	13	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	mouth disease	targetBased	0.141229320869979	8	46715	2829
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	mouth disease	targetBased	0.188762530959518	58	57013	201
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	mouth disease	targetBased	0.222452538352194	17	343468	285
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	mouth disease	targetBased	0.195791921694685	8	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	mouth disease	targetBased	0.195791921694685	8	335239	695
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	mouth disease	targetBased	0.130503465707649	8	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	mouth disease	targetBased	0.1809801953265	54	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	mouth disease	pathwayBased	0.1809801953265	54	403871	1243
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	mouth disease	targetBased	0.129719180225366	6	369953	3123
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	mouth disease	targetBased	0.119348171793671	4	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	mouth disease	targetBased	0.156905161179501	6	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	mouth disease	targetBased	0.114749040297401	39	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	mouth disease	targetBased	0.114749040297401	39	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	mouth disease	targetBased	0.114749040297401	39	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	mouth disease	targetBased	0.114749040297401	39	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	mouth disease	targetBased	0.114749040297401	39	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	mouth disease	targetBased	0.114749040297401	39	196177	519
E3 Ligase HTS_1536	MDM2	mouth disease	targetBased	0.128922285654411	49	207811	220
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	mouth disease	targetBased	0.158455586552102	23	322361	619
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	mouth disease	targetBased	0.159660561892357	11	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	mouth disease	targetBased	0.159660561892357	11	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	mouth disease	targetBased	0.141921681169004	4	71016	346
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	mouth disease	targetBased	0.202945655379324	52	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	mouth disease	pathwayBased	0.148394046074413	158	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	mouth disease	pathwayBased	0.148394046074413	158	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	mouth disease	targetBased	0.210608525065713	13	339297	1446
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	mouth disease	targetBased	0.243574122274198	53	194628	267
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	mouth disease	targetBased	0.140370872375495	7	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	mouth disease	targetBased	0.140370872375495	7	331360	2760
HCS assay for microtubule stabilizers	TUBB	mouth disease	targetBased	0.142666772845746	24	195821	1625
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	mouth disease	targetBased	0.17910282870345	38	316642	617
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	mouth disease	pathwayBased	0.157141739120913	175	43989	342
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	mouth disease	targetBased	0.189544391571219	44	343468	734
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	mouth disease	targetBased	0.134566651280402	10	309684	1662
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	gastroenteritis	targetBased	0.154633806653938	7	194152	1342
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	gastroenteritis	targetBased	0.218506072992008	26	326888	645
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	gastroenteritis	targetBased	0.173203417600584	9	363803	458
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	gastroenteritis	targetBased	0.196694290124942	12	217959	771
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	gastroenteritis	targetBased	0.196694290124942	12	217959	569
HTS of Smad transcription factor inhibitors	SMAD3	gastroenteritis	targetBased	0.16044344143482	28	88033	251
OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	gastroenteritis	targetBased	0.114483639503231	14	47480	334
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	gastroenteritis	targetBased	0.110253624464568	80	394050	3624
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	gastroenteritis	targetBased	0.214171489449838	52	55710	315
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Abnormal abdomen morphology	targetBased	0.225725453668566	99	217959	2390
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Abnormal intestine morphology	pathwayBased	0.121772986122181	4	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormal intestine morphology	targetBased	0.121772986122181	4	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormal intestine morphology	targetBased	0.121772986122181	4	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormal intestine morphology	targetBased	0.121772986122181	4	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormal intestine morphology	targetBased	0.121772986122181	4	124022	1156
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Abnormal gastrointestinal tract morphology	pathwayBased	0.123067376409661	13	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormal gastrointestinal tract morphology	targetBased	0.123067376409661	13	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormal gastrointestinal tract morphology	targetBased	0.123067376409661	13	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormal gastrointestinal tract morphology	targetBased	0.123067376409661	13	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormal gastrointestinal tract morphology	targetBased	0.123067376409661	13	124022	1156
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Abnormal gastrointestinal tract morphology	targetBased	0.207827625009424	5	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Abnormal gastrointestinal tract morphology	targetBased	0.207827625009424	5	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Abnormal gastrointestinal tract morphology	targetBased	0.207827625009424	5	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Abnormal gastrointestinal tract morphology	targetBased	0.207827625009424	5	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Abnormal gastrointestinal tract morphology	targetBased	0.207827625009424	5	359207	4555
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	Functional abnormality of the gastrointestinal tract	targetBased	0.140147038104654	13	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	Functional abnormality of the gastrointestinal tract	targetBased	0.140147038104654	13	296501	2737
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Functional abnormality of the gastrointestinal tract	targetBased	0.204721142769349	5	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Functional abnormality of the gastrointestinal tract	targetBased	0.204721142769349	5	335239	695
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Functional abnormality of the gastrointestinal tract	targetBased	0.17251169168788	5	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Functional abnormality of the gastrointestinal tract	targetBased	0.17251169168788	5	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Functional abnormality of the gastrointestinal tract	targetBased	0.17251169168788	5	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Functional abnormality of the gastrointestinal tract	targetBased	0.17251169168788	5	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Functional abnormality of the gastrointestinal tract	targetBased	0.17251169168788	5	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Functional abnormality of the gastrointestinal tract	targetBased	0.17251169168788	5	196177	519
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	Abnormality of the gastrointestinal tract	targetBased	0.150809719053129	18	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	Abnormality of the gastrointestinal tract	targetBased	0.150809719053129	18	296501	2737
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Abnormality of the gastrointestinal tract	pathwayBased	0.12524806865127	20	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormality of the gastrointestinal tract	targetBased	0.12524806865127	20	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormality of the gastrointestinal tract	targetBased	0.12524806865127	20	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormality of the gastrointestinal tract	targetBased	0.12524806865127	20	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormality of the gastrointestinal tract	targetBased	0.12524806865127	20	124022	1156
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Abnormality of the gastrointestinal tract	targetBased	0.20917999349553	5	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Abnormality of the gastrointestinal tract	targetBased	0.20917999349553	5	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Abnormality of the gastrointestinal tract	targetBased	0.20917999349553	5	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Abnormality of the gastrointestinal tract	targetBased	0.20917999349553	5	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Abnormality of the gastrointestinal tract	targetBased	0.20917999349553	5	359207	4555
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	Abnormality of the digestive system	targetBased	0.256738770550522	72	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	Abnormality of the digestive system	targetBased	0.256738770550522	72	296501	2737
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	Abnormality of the digestive system	targetBased	0.206711417313871	13	290355	265
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	Abnormality of the digestive system	targetBased	0.22706601916472	131	217959	2390
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	Abnormality of the digestive system	targetBased	0.222081786350855	46	363803	2412
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Abnormality of the digestive system	targetBased	0.222689384826116	127	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Abnormality of the digestive system	targetBased	0.222689384826116	127	335239	695
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	Abnormality of the digestive system	targetBased	0.14276286347638	129	405130	6428
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	Abnormality of the digestive system	targetBased	0.14276286347638	129	373462	23
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	Abnormality of the digestive system	targetBased	0.14276286347638	129	405130	6428
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	Abnormality of the digestive system	targetBased	0.203843720207239	11	306502	3633
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	Abnormality of the digestive system	targetBased	0.203843720207239	11	335180	1022
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the digestive system	targetBased	0.194395799123269	302	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the digestive system	targetBased	0.194395799123269	302	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the digestive system	targetBased	0.194395799123269	302	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the digestive system	targetBased	0.194395799123269	302	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the digestive system	targetBased	0.194395799123269	302	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	Abnormality of the digestive system	targetBased	0.194395799123269	302	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	Abnormality of the digestive system	targetBased	0.126088196007265	9	263421	615
qHTS assay for re-activators of p53 using a Luc reporter	TP53	Abnormality of the digestive system	pathwayBased	0.12682763748055	137	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormality of the digestive system	targetBased	0.12682763748055	137	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormality of the digestive system	targetBased	0.12682763748055	137	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormality of the digestive system	targetBased	0.12682763748055	137	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	Abnormality of the digestive system	targetBased	0.12682763748055	137	124022	1156
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	Abnormality of the digestive system	targetBased	0.220531063776147	54	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	Abnormality of the digestive system	targetBased	0.220531063776147	54	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	Abnormality of the digestive system	targetBased	0.220531063776147	54	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	Abnormality of the digestive system	targetBased	0.220531063776147	54	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	Abnormality of the digestive system	targetBased	0.220531063776147	54	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	Abnormality of the digestive system	targetBased	0.220531063776147	54	336308	6862
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	Abnormality of the digestive system	targetBased	0.215321018787221	24	364051	9106
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	Abnormality of the digestive system	targetBased	0.215321018787221	24	407539	2380
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	Abnormality of the digestive system	targetBased	0.215321018787221	24	407539	2380
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	Abnormality of the digestive system	targetBased	0.130492759443414	14	325630	216
Counterscreen for agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	Abnormality of the digestive system	targetBased	0.188838073316936	19	335239	2035
Counterscreen for inverse agonists of OPRM1-OPRD1 heterodimerization: luminescence-based cell-based full-deck high throughput screening assay to identify inverse agonists of 5-hydroxytryptamine (serotonin) 5A receptor (HTR5A)	HTR5A	Abnormality of the digestive system	targetBased	0.188838073316936	19	335239	279
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	Abnormality of the digestive system	targetBased	0.125466136055478	6	335531	328
Dyrk1 A HTS Measured in Biochemical System Using Plate Reader - 2124-01_Inhibitor_SinglePoint_HTS_Activity	DYRK1A_inhibitors	Abnormality of the digestive system	targetBased	0.185079044650762	4	310014	1321
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	Abnormality of the digestive system	targetBased	0.201420259688976	4	324747	813
Primary Cell Based High Throughput Screening Assay for Agonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	Abnormality of the digestive system	targetBased	0.18739589566178	4	64908	446
Primary Cell Based High Throughput Screening Assay for Antagonists of the 5-Hydroxytryptamine Receptor Subtype 1E (5HT1E)	HTR1E	Abnormality of the digestive system	targetBased	0.18739589566178	4	64908	641
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	Abnormality of the digestive system	targetBased	0.17687633711971	8	339297	1446
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	Abnormality of the digestive system	targetBased	0.201490789047156	16	64908	366
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	Abnormality of the digestive system	targetBased	0.201490789047156	16	61606	416
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	Abnormality of the digestive system	targetBased	0.210513177077567	27	316642	617
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Abnormality of the gastrointestinal tract	targetBased	0.204721142769349	5	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	Abnormality of the gastrointestinal tract	targetBased	0.204721142769349	5	335239	695
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	Abnormality of the digestive system	pathwayBased	0.170143595846741	45	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	Abnormality of the digestive system	targetBased	0.170143595846741	45	195980	695
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	Abnormality of the digestive system	targetBased	0.216848951258122	14	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	Abnormality of the digestive system	targetBased	0.216848951258122	14	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	Abnormality of the digestive system	targetBased	0.216848951258122	14	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	Abnormality of the digestive system	targetBased	0.216848951258122	14	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	Abnormality of the digestive system	targetBased	0.216848951258122	14	359207	4555
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	cecal disorder	targetBased	0.19332836794129	10	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	cecal disorder	targetBased	0.19332836794129	10	337446	1356
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	cecal disorder	targetBased	0.127938133524008	5	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	cecal disorder	targetBased	0.127938133524008	5	86095	1151
qHTS assay for re-activators of p53 using a Luc reporter	TP53	cecal disorder	pathwayBased	0.187425053136919	16	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cecal disorder	targetBased	0.187425053136919	16	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cecal disorder	targetBased	0.187425053136919	16	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cecal disorder	targetBased	0.187425053136919	16	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	cecal disorder	targetBased	0.187425053136919	16	124022	1156
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	cecal disorder	targetBased	0.145496487674544	7	193542	587
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	functional gastric disease	targetBased	0.212795330133383	18	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	functional gastric disease	targetBased	0.212795330133383	18	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	functional gastric disease	targetBased	0.212795330133383	18	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	functional gastric disease	targetBased	0.212795330133383	18	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	functional gastric disease	targetBased	0.212795330133383	18	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	functional gastric disease	targetBased	0.212795330133383	18	336308	6862
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	duodenal disorder	targetBased	0.118625969456299	4	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	duodenal disorder	targetBased	0.118625969456299	4	86095	1151
qHTS assay for re-activators of p53 using a Luc reporter	TP53	duodenal disorder	pathwayBased	0.128317533150862	22	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	duodenal disorder	targetBased	0.128317533150862	22	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	duodenal disorder	targetBased	0.128317533150862	22	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	duodenal disorder	targetBased	0.128317533150862	22	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	duodenal disorder	targetBased	0.128317533150862	22	124022	1156
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	duodenal disorder	targetBased	0.12808550586189	7	193542	587
qHTS assay for re-activators of p53 using a Luc reporter	TP53	common bile duct disorder	pathwayBased	0.102954655136439	16	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	common bile duct disorder	targetBased	0.102954655136439	16	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	common bile duct disorder	targetBased	0.102954655136439	16	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	common bile duct disorder	targetBased	0.102954655136439	16	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	common bile duct disorder	targetBased	0.102954655136439	16	124022	1156
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	common bile duct disorder	targetBased	0.102714256663671	5	193542	587
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	bile duct disorder	targetBased	0.174865308917946	22	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	bile duct disorder	targetBased	0.174865308917946	22	296501	2737
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	bile duct disorder	pathwayBased	0.20131006530027	22	376029	3978
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	bile duct disorder	targetBased	0.137038067316657	7	336894	489
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	bile duct disorder	targetBased	0.213737927874595	13	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	bile duct disorder	targetBased	0.213737927874595	13	337446	1356
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	bile duct disorder	targetBased	0.154814997950924	9	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	bile duct disorder	targetBased	0.136225872415485	5	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	bile duct disorder	pathwayBased	0.165148000435158	7	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	bile duct disorder	pathwayBased	0.165148000435158	7	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	bile duct disorder	targetBased	0.179948592537697	4	46715	2829
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	bile duct disorder	targetBased	0.160115406202768	16	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	bile duct disorder	targetBased	0.160115406202768	16	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	bile duct disorder	targetBased	0.160115406202768	16	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	bile duct disorder	targetBased	0.160115406202768	16	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	bile duct disorder	targetBased	0.160115406202768	16	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	bile duct disorder	targetBased	0.160115406202768	16	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	bile duct disorder	targetBased	0.130204215901408	4	263421	615
E3 Ligase HTS_1536	MDM2	bile duct disorder	targetBased	0.133004755719711	12	207811	220
USP8 deubiquitinase inhibition: Primary qHTS	USP8	bile duct disorder	targetBased	0.167217702290312	6	47480	2010
qHTS assay for re-activators of p53 using a Luc reporter	TP53	bile duct disorder	pathwayBased	0.23149539481692	258	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bile duct disorder	targetBased	0.23149539481692	258	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bile duct disorder	targetBased	0.23149539481692	258	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bile duct disorder	targetBased	0.23149539481692	258	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	bile duct disorder	targetBased	0.23149539481692	258	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	bile duct disorder	targetBased	0.141311460105292	195	356517	1139
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	bile duct disorder	targetBased	0.16887908609418	36	57013	201
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	bile duct disorder	targetBased	0.121412241828512	5	343468	285
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	bile duct disorder	targetBased	0.187341777733047	13	322361	619
Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.	BCL2L11_inhibitors	bile duct disorder	targetBased	0.12089254391814	6	325630	216
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	bile duct disorder	targetBased	0.178470306332188	11	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	bile duct disorder	pathwayBased	0.178470306332188	11	403871	1243
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	bile duct disorder	targetBased	0.127307347889318	10	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	bile duct disorder	targetBased	0.127307347889318	10	218234	1620
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	bile duct disorder	targetBased	0.139236852916198	6	344733	7043
HTS of Smad transcription factor inhibitors	SMAD3	bile duct disorder	targetBased	0.201213887756849	7	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	bile duct disorder	targetBased	0.174976088167904	30	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	bile duct disorder	pathwayBased	0.193756604488533	85	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	bile duct disorder	pathwayBased	0.193756604488533	85	194666	1722
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	bile duct disorder	targetBased	0.126366415720639	7	194628	267
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	bile duct disorder	targetBased	0.162262749483003	4	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	bile duct disorder	targetBased	0.162262749483003	4	331360	2760
HCS assay for microtubule stabilizers	TUBB	bile duct disorder	targetBased	0.109952188057476	8	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	bile duct disorder	targetBased	0.140711123544983	4	347933	673
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	bile duct disorder	pathwayBased	0.178767110927498	70	43989	342
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	bile duct disorder	targetBased	0.23355036797594	18	71016	346
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	colonic disorder	pathwayBased	0.171969034534272	19	376029	3978
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	colonic disorder	pathwayBased	0.119078994116249	4	358556	3721
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	colonic disorder	targetBased	0.206755728378382	20	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	colonic disorder	targetBased	0.206755728378382	20	337446	1356
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	colonic disorder	targetBased	0.154836661926854	8	194152	1342
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	colonic disorder	targetBased	0.17564256735242	13	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	colonic disorder	pathwayBased	0.137120646637068	21	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	colonic disorder	pathwayBased	0.137120646637068	21	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	colonic disorder	targetBased	0.105332600461581	4	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	colonic disorder	targetBased	0.150027571590027	13	46715	2829
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	colonic disorder	targetBased	0.150869237746611	39	57013	201
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	colonic disorder	targetBased	0.118256571076123	206	324747	7988
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	colonic disorder	targetBased	0.134060467132072	100	394050	3624
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	colonic disorder	targetBased	0.148314488009712	12	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	colonic disorder	targetBased	0.148314488009712	12	335239	695
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	colonic disorder	targetBased	0.140052889942164	29	363840	2624
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	colonic disorder	targetBased	0.173251015934994	11	363803	458
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	colonic disorder	targetBased	0.136562113378297	5	369953	3123
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	colonic disorder	targetBased	0.196694290124942	12	217959	771
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	colonic disorder	targetBased	0.196694290124942	12	217959	569
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	colonic disorder	targetBased	0.158193707487123	13	344733	7043
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	colonic disorder	targetBased	0.141552184045967	4	263421	615
E3 Ligase HTS_1536	MDM2	colonic disorder	targetBased	0.130889585483313	22	207811	220
qHTS assay for re-activators of p53 using a Luc reporter	TP53	colonic disorder	pathwayBased	0.270593269175145	738	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colonic disorder	targetBased	0.270593269175145	738	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colonic disorder	targetBased	0.270593269175145	738	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colonic disorder	targetBased	0.270593269175145	738	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	colonic disorder	targetBased	0.270593269175145	738	124022	1156
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	colonic disorder	pathwayBased	0.134146780130385	31	7671	874
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	colonic disorder	targetBased	0.134146780130385	31	304060	10600
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	colonic disorder	pathwayBased	0.134146780130385	31	305439	16717
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	colonic disorder	targetBased	0.239854198195393	32	322361	619
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	colonic disorder	targetBased	0.136151997586347	8	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	colonic disorder	targetBased	0.136151997586347	8	218234	1620
qHTS for Inhibitors of WRN Helicase	WRN	colonic disorder	targetBased	0.141868638271716	5	364011	1678
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	colonic disorder	targetBased	0.210871674012731	127	193542	587
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	colonic disorder	targetBased	0.171144866526617	6	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	colonic disorder	targetBased	0.171144866526617	6	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	colonic disorder	targetBased	0.171144866526617	6	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	colonic disorder	targetBased	0.171144866526617	6	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	colonic disorder	targetBased	0.171144866526617	6	359207	4555
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	colonic disorder	pathwayBased	0.170398017381564	437	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	colonic disorder	pathwayBased	0.170398017381564	437	194666	1722
OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	colonic disorder	targetBased	0.114461038153715	14	47480	334
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	colonic disorder	targetBased	0.134962083210579	24	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	colonic disorder	targetBased	0.120716228382883	25	218654	8241
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	colonic disorder	targetBased	0.142164694272799	5	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	colonic disorder	targetBased	0.163813569462516	7	331671	10022
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	colonic disorder	targetBased	0.118726777754187	76	343468	734
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	colonic disorder	targetBased	0.218518199680198	29	326888	645
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	colonic disorder	targetBased	0.143955993792195	4	71016	346
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	colonic disorder	targetBased	0.142529530078371	7	339297	1446
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	colonic disorder	targetBased	0.21417134494104	53	55710	315
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	intestinal motility disease	targetBased	0.141409588541882	19	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	intestinal motility disease	targetBased	0.141409588541882	19	331360	2760
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	large intestine disorder	targetBased	0.134288562643021	49	343786	1253
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	large intestine disorder	targetBased	0.134288562643021	49	296501	2737
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	large intestine disorder	pathwayBased	0.228070992027438	174	376029	3978
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	large intestine disorder	pathwayBased	0.137269222426945	7	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	large intestine disorder	targetBased	0.152217052094048	40	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	large intestine disorder	targetBased	0.105595795953788	23	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	large intestine disorder	targetBased	0.105595795953788	23	290726	2649
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	large intestine disorder	targetBased	0.262908010888668	38	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	large intestine disorder	targetBased	0.262908010888668	38	337446	1356
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	large intestine disorder	targetBased	0.147064437995335	4	385746	932
uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary Assays	DiaphoraseInhibitors	large intestine disorder	targetBased	0.154836661926854	8	194152	1342
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	large intestine disorder	targetBased	0.180886152989967	137	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	large intestine disorder	targetBased	0.180886152989967	137	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	large intestine disorder	targetBased	0.265429919371432	94	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	large intestine disorder	targetBased	0.248782143633107	69	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	large intestine disorder	pathwayBased	0.166657014789683	32	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	large intestine disorder	pathwayBased	0.166657014789683	32	131324	544
ROC1-CUL1 CTD Inhibitor di-Ub FRET Primary HTS Screen	RBX1	large intestine disorder	targetBased	0.127197447305982	9	143816	859
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	large intestine disorder	targetBased	0.201690279516929	23	46715	2829
Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)	KLF5	large intestine disorder	targetBased	0.162146041970988	19	290726	671
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	large intestine disorder	targetBased	0.16133729345169	62	57013	201
Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR)	AHR_activators	large intestine disorder	targetBased	0.118615639408968	214	324747	7988
Primary qHTS assay for inhibitors of human arachidonate 12S-lipoxygenase (ALOX12): Round 2	ALOX12_inhibitors	large intestine disorder	targetBased	0.185342811611515	7	564288	6030
Fluorescence polarization-based biochemical primary high throughput screening assay to identify activators of the Protein Kinase A-R1A (PKA-R1A) complex	PRKAR1A	large intestine disorder	targetBased	0.151250675861181	4	343468	285
High Throughput Screen to Identify Compounds that increase expression of NF-kB in Human Neuronal Cells - Primary Screen	NFKB1	large intestine disorder	pathwayBased	0.168756070360562	1234	193265	3100
uHTS identification of cystic fibrosis induced NFkb Inhibitors in a fluoresence assay	NFKB1	large intestine disorder	pathwayBased	0.168756070360562	1234	359244	3094
Development of Small Molecule Probes of the Histone Methyltransferase, NSD2 Measured in Biochemical System Using Plate Reader - 7053-01_Inhibitor_SinglePoint_HTS_Activity_Set2	NSD2	large intestine disorder	targetBased	0.179296826058977	4	309684	1662
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	large intestine disorder	targetBased	0.106765490762238	35	338328	2501
Toxoplasma gondii inhibition HTS in the presence of IFN-y	IFNG	large intestine disorder	targetBased	0.148885738507163	891	67275	2509
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	large intestine disorder	targetBased	0.190608258230326	16	335239	991
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	large intestine disorder	targetBased	0.190608258230326	16	335239	695
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	large intestine disorder	targetBased	0.218647213853752	36	326888	645
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	large intestine disorder	targetBased	0.18983241777785	45	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	large intestine disorder	targetBased	0.176520859496463	68	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	large intestine disorder	pathwayBased	0.176520859496463	68	403871	1243
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of the liver receptor homolog-1 (LRH-1; NR5A2)	NR5A2	large intestine disorder	targetBased	0.173904853987899	14	363803	458
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	large intestine disorder	targetBased	0.151722082053047	12	369953	3123
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	large intestine disorder	targetBased	0.18095958189554	5	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	large intestine disorder	targetBased	0.206512918988513	28	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	large intestine disorder	targetBased	0.282586404960039	355	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	large intestine disorder	targetBased	0.282586404960039	355	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	large intestine disorder	targetBased	0.282586404960039	355	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	large intestine disorder	targetBased	0.282586404960039	355	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	large intestine disorder	targetBased	0.282586404960039	355	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	large intestine disorder	targetBased	0.282586404960039	355	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	large intestine disorder	targetBased	0.158167540689965	24	263421	615
E3 Ligase HTS_1536	MDM2	large intestine disorder	targetBased	0.16441991437163	51	207811	220
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac activated mutant	RAC1	large intestine disorder	targetBased	0.158796742418323	5	194629	219
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Rac wildtype	RAC1	large intestine disorder	targetBased	0.158796742418323	5	194628	521
High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6)	TRPC6	large intestine disorder	targetBased	0.148806690762262	4	305610	382
High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6)	TRPC6	large intestine disorder	targetBased	0.148806690762262	4	305610	3253
HTS for Estrogen Receptor-beta Coactivator Binding inhibitors	ESR2_inhibitors	large intestine disorder	targetBased	0.106512728895391	66	86095	1114
Luminescence-based cell-based primary high throughput screening assay to identify inhibitors of the Steroid Receptor Coactivator 2 (SRC2; NCOA2)	NCOA2	large intestine disorder	targetBased	0.147351816298633	4	368927	620
qHTS assay for re-activators of p53 using a Luc reporter	TP53	large intestine disorder	pathwayBased	0.308826611252678	1700	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	large intestine disorder	targetBased	0.308826611252678	1700	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	large intestine disorder	targetBased	0.308826611252678	1700	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	large intestine disorder	targetBased	0.308826611252678	1700	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	large intestine disorder	targetBased	0.308826611252678	1700	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	large intestine disorder	targetBased	0.252625920860032	436	356517	1139
qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway	RORCgammaPathwayInhibitors	large intestine disorder	pathwayBased	0.134171960841018	32	7671	874
VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity	RORC	large intestine disorder	targetBased	0.134171960841018	32	304060	10600
qHTS for inhibitors of ROR gamma transcriptional activity	RORCgammaPathwayInhibitors	large intestine disorder	pathwayBased	0.134171960841018	32	305439	16717
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	large intestine disorder	targetBased	0.282794549839539	83	322361	619
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	large intestine disorder	targetBased	0.19080672363384	7	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	large intestine disorder	targetBased	0.151260865961722	14	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	large intestine disorder	targetBased	0.151260865961722	14	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	large intestine disorder	targetBased	0.160579437976138	15	71016	346
qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase)	HPGD	large intestine disorder	targetBased	0.156940032625911	32	148480	6428
Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3	procaspase3Activators	large intestine disorder	targetBased	0.103830713271118	178	326024	350
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of HIV-1 LEDGF/p75 DNA Integration	PSIP1	large intestine disorder	targetBased	0.180924363966214	4	369953	2353
qHTS for Inhibitors of WRN Helicase	WRN	large intestine disorder	targetBased	0.242766866989144	14	364011	1678
HTS of Smad transcription factor inhibitors	SMAD3	large intestine disorder	targetBased	0.274803506856109	63	88033	251
uHTS luminescence assay for the identification of compounds that inhibit NOD2	NOD2	large intestine disorder	targetBased	0.268452113239036	209	292323	1836
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	large intestine disorder	targetBased	0.268417094971807	316	193542	587
qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).	FEN1_inhibitors	large intestine disorder	targetBased	0.102871363335938	9	386270	1331
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	large intestine disorder	targetBased	0.171255692417983	7	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	large intestine disorder	targetBased	0.171255692417983	7	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	large intestine disorder	targetBased	0.171255692417983	7	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	large intestine disorder	targetBased	0.171255692417983	7	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	large intestine disorder	targetBased	0.171255692417983	7	359207	4555
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	large intestine disorder	pathwayBased	0.180895637808501	538	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	large intestine disorder	pathwayBased	0.180895637808501	538	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	large intestine disorder	targetBased	0.164748862791827	10	339297	1446
OTUD3 deubiquitinase inhibition: Primary qHTS	OTUD3	large intestine disorder	targetBased	0.114461038153715	14	47480	334
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	large intestine disorder	targetBased	0.214172012932599	54	55710	315
SMM ID4 Measured in Biochemical System Using Small Molecule MicroArray - 2128-01_Other_SinglePoint_HTS_Activity	ID4	large intestine disorder	targetBased	0.109491079300376	5	31324	362
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	large intestine disorder	targetBased	0.192735364165936	50	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	large intestine disorder	targetBased	0.144664582738475	28	218654	8241
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	large intestine disorder	targetBased	0.146961132069313	4	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	large intestine disorder	targetBased	0.146961132069313	4	331360	2760
HCS assay for microtubule stabilizers	TUBB	large intestine disorder	targetBased	0.13858808472361	22	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	large intestine disorder	targetBased	0.206431590747704	10	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	large intestine disorder	targetBased	0.176617717104892	9	331671	10022
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	large intestine disorder	pathwayBased	0.243370349404526	204	43989	342
Fluorescence-based cell-based primary high throughput screening assay to identify inhibitors of TLR9-MyD88 binding.	TLR9	large intestine disorder	targetBased	0.122298397346858	89	343468	734
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	small intestine disorder	pathwayBased	0.146609163791844	9	376029	3978
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	small intestine disorder	targetBased	0.110887129309367	10	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	small intestine disorder	targetBased	0.110887129309367	10	290726	2649
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	small intestine disorder	targetBased	0.13967346679307	11	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	small intestine disorder	targetBased	0.13967346679307	11	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	small intestine disorder	targetBased	0.153536662523345	6	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	small intestine disorder	targetBased	0.25147180143239	110	359207	1432
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	small intestine disorder	targetBased	0.153606520546873	5	57013	201
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	small intestine disorder	targetBased	0.183116719254692	6	326888	645
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	small intestine disorder	targetBased	0.130490597561264	6	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	small intestine disorder	targetBased	0.130490597561264	6	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	small intestine disorder	targetBased	0.130490597561264	6	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	small intestine disorder	targetBased	0.130490597561264	6	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	small intestine disorder	targetBased	0.130490597561264	6	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	small intestine disorder	targetBased	0.130490597561264	6	196177	519
E3 Ligase HTS_1536	MDM2	small intestine disorder	targetBased	0.105240693047513	15	207811	220
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	small intestine disorder	targetBased	0.152156055151324	8	322361	619
HTS of Smad transcription factor inhibitors	SMAD3	small intestine disorder	targetBased	0.168462445655091	5	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	small intestine disorder	targetBased	0.154124167510169	26	193542	587
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	small intestine disorder	pathwayBased	0.143732553309557	17	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	small intestine disorder	pathwayBased	0.143732553309557	17	194666	1722
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	small intestine disorder	targetBased	0.131497388941931	6	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	small intestine disorder	targetBased	0.131497388941931	6	331360	2760
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	small intestine disorder	pathwayBased	0.154410166348749	35	43989	342
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	large intestine disorder	targetBased	0.150399635675161	127	394050	3624
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	large intestine disorder	targetBased	0.196798431967435	13	217959	771
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	large intestine disorder	targetBased	0.196798431967435	13	217959	569
USP8 deubiquitinase inhibition: Primary qHTS	USP8	large intestine disorder	targetBased	0.14844873740403	4	47480	2010
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	small intestine disorder	targetBased	0.162424730271162	6	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	small intestine disorder	targetBased	0.162424730271162	6	337446	1356
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	small intestine disorder	targetBased	0.181503795636043	17	263421	615
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	small intestine disorder	targetBased	0.100474343332503	59	356517	1139
qHTS Assay to Identify Small Molecule Activators of BRCA1 Expression	BRCA1 activation	upper digestive tract disorder	pathwayBased	0.161486644810321	34	376029	3978
HTS to identify compounds that promote myeloid differentiation with MLPCN compound set	HOXA9	upper digestive tract disorder	pathwayBased	0.102580658913278	6	358556	3721
Fluorescence polarization to screen for inhibitors that disrupt the protein-protein interaction between Keap1 and Nrf2 Measured in Biochemical System Using Plate Reader - 2119-01_Inhibitor_SinglePoint_HTS_Activity	KEAP1	upper digestive tract disorder	targetBased	0.150321032541733	24	336894	489
HTS for Tumor Hsp90 Inhibitors	HSP90 known inhibitor displacement	upper digestive tract disorder	targetBased	0.116999052702556	17	63696	220
Luminescence-based primary biochemical high throughput screening assay to identify inhibitors of the Heat Shock Protein 90 (HSP90)	HSP90AA1	upper digestive tract disorder	targetBased	0.116999052702556	17	290726	2649
qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	upper digestive tract disorder	targetBased	0.145034469060499	4	334825	423
qHTS for Antagonists of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS	GNAS	upper digestive tract disorder	targetBased	0.145034469060499	4	337446	1356
qHTS for Suppressors of FUS Proteinopathy: Primary screen using FUS-linked yeast assay	FUS_asupressors	upper digestive tract disorder	targetBased	0.138614614299397	4	385746	932
HTS of Estrogen Receptor- alpha Coactivator Binding inhibitors	ESR1_inhibitors	upper digestive tract disorder	targetBased	0.206900623767966	52	86095	1442
HTS of Estrogen Receptor- alpha Coactivator Binding Potentiators	ESR1_modulators	upper digestive tract disorder	targetBased	0.206900623767966	52	86095	1151
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	upper digestive tract disorder	targetBased	0.165730732956527	31	217959	2390
TRFRET-based biochemical primary high throughput screening assay to identify inhibitors of the interaction of the Ras and Rab interactor 1 protein (Rin1) and the c-abl oncogene 1, non-receptor tyrosine kinase (Abl)	ABL1_interaction	upper digestive tract disorder	targetBased	0.167853003223802	11	359207	1432
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay	MAPK1	upper digestive tract disorder	pathwayBased	0.167328604663591	17	70898	707
qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF	MAPK1	upper digestive tract disorder	pathwayBased	0.167328604663591	17	131324	544
Dicer-mediated maturation of pre-microRNA	Dicer_inhibitors	upper digestive tract disorder	targetBased	0.139952719795136	9	46715	2829
EZH2/PRC2 methyltransferase inhibitors Measured in Biochemical System Using Plate Reader - 2125-01_Inhibitor_SinglePoint_HTS_Activity	EZH2_inhibitors	upper digestive tract disorder	targetBased	0.156301703572436	50	57013	201
Primary qHTS assay for inhibitors of human arachidonate 12S-lipoxygenase (ALOX12): Round 2	ALOX12_inhibitors	upper digestive tract disorder	targetBased	0.177237887811495	6	564288	6030
uHTS identification of Gli-Sufu Antagonists in a luminescence reporter assay	GLI1	upper digestive tract disorder	targetBased	0.101711451740033	38	338328	2501
uHTS identification of HIF-2a Inhibitors in a luminesence assay	HIF-2a_inhibitors	upper digestive tract disorder	targetBased	0.168042672120834	9	363840	2624
Nrf2 qHTS screen for inhibitors	nrf2Inhibitors	upper digestive tract disorder	targetBased	0.219137549973724	58	360873	7438
qHTS of Nrf2 Activators	Nrf2 activators	upper digestive tract disorder	pathwayBased	0.219137549973724	58	403871	1243
Fluorescence-based biochemical high throughput primary assay to identify inhibitors of phospholipase C isozymes (PLC-gamma1).	PLCG1	upper digestive tract disorder	targetBased	0.135230274597126	4	369953	3123
qHTS Assay for Inhibitors of the Six1/Eya2 Interaction	SIX1	upper digestive tract disorder	targetBased	0.134387167760908	8	364053	2026
Screen for inhibitors of the SWI/SNF chromatin remodeling complex (esBAF) in mouse embryonic stem cells with Luciferase reporter assay Measured in Cell-Based System Using Plate Reader - 2141-01_Inhibitor_SinglePoint_HTS_Activity	SMARCA4	upper digestive tract disorder	targetBased	0.216144931591686	19	344733	7043
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	upper digestive tract disorder	targetBased	0.137898774203478	35	99314	335
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	upper digestive tract disorder	targetBased	0.137898774203478	35	196176	782
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	upper digestive tract disorder	targetBased	0.137898774203478	35	99314	390
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	upper digestive tract disorder	targetBased	0.137898774203478	35	196177	811
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	upper digestive tract disorder	targetBased	0.137898774203478	35	196176	670
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	upper digestive tract disorder	targetBased	0.137898774203478	35	196177	519
qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide	Menin-MLL_inhibitors	upper digestive tract disorder	targetBased	0.119075651192838	8	263421	615
E3 Ligase HTS_1536	MDM2	upper digestive tract disorder	targetBased	0.166792459560453	68	207811	220
USP8 deubiquitinase inhibition: Primary qHTS	USP8	upper digestive tract disorder	targetBased	0.136683970652793	5	47480	2010
qHTS assay for re-activators of p53 using a Luc reporter	TP53	upper digestive tract disorder	pathwayBased	0.286509685530083	976	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	upper digestive tract disorder	targetBased	0.286509685530083	976	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	upper digestive tract disorder	targetBased	0.286509685530083	976	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	upper digestive tract disorder	targetBased	0.286509685530083	976	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	upper digestive tract disorder	targetBased	0.286509685530083	976	124022	1156
HTS Assay for Inhibitors of Akt Phophorylation: Primary Screen	AKT1_inhibitors	upper digestive tract disorder	targetBased	0.14439203425888	387	356517	1139
Inhibitors of CDC25B-CDK2/CyclinA interaction	Inhibitors of CDC25B-CDK2/CyclinA interaction	upper digestive tract disorder	targetBased	0.112949418858417	31	93798	679
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	upper digestive tract disorder	targetBased	0.21142960820566	7	359518	300
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	upper digestive tract disorder	targetBased	0.21142960820566	7	335652	1779
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	upper digestive tract disorder	targetBased	0.21142960820566	7	357537	806
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	upper digestive tract disorder	targetBased	0.21142960820566	7	339887	1178
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	upper digestive tract disorder	targetBased	0.21142960820566	7	362274	1056
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	upper digestive tract disorder	targetBased	0.21142960820566	7	336308	6862
qHTS Assay for Identifying a Potential Treatment of Ataxia-Telangiectasia	ATM_modulators	upper digestive tract disorder	targetBased	0.175103949253225	42	322361	619
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	upper digestive tract disorder	targetBased	0.173560529730411	4	335531	328
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	upper digestive tract disorder	targetBased	0.153695536467353	15	215667	993
uHTS identification of compounds inhibiting the binding between the RUNX1 Runt domain and CBFb-SMMHC via a fluorescence resonance energy transfer (FRET) assay.	RUNX1	upper digestive tract disorder	targetBased	0.153695536467353	15	218234	1620
HTS for BAP1 Enzyme inhibitors	BAP1_inhibitors	upper digestive tract disorder	targetBased	0.166506375767279	6	71016	346
uHTS for 14-3-3/Bad interaction inhibitors	YWHAZ	upper digestive tract disorder	targetBased	0.102570759914913	7	217332	1549
qHTS for Inhibitors of WRN Helicase	WRN	upper digestive tract disorder	targetBased	0.191754715622543	7	364011	1678
HTS of Smad transcription factor inhibitors	SMAD3	upper digestive tract disorder	targetBased	0.194916238556379	22	88033	251
High Throughput Imaging Assay for Beta-Catenin	betaCateninTranslocation	upper digestive tract disorder	targetBased	0.192213291090885	53	193542	587
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	ulcer disease	targetBased	0.206158034285837	4	359207	1189
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	ulcer disease	targetBased	0.206158034285837	4	63676	1938
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	ulcer disease	targetBased	0.206158034285837	4	359207	316
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	ulcer disease	targetBased	0.206158034285837	4	63656	2179
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	ulcer disease	targetBased	0.206158034285837	4	359207	4555
Primary cell-based high throughput screening assay to measure STAT3 activation	STAT3	upper digestive tract disorder	pathwayBased	0.162360550737552	170	194666	1772
Primary cell-based high throughput screening assay to measure STAT3 inhibition	STAT3	upper digestive tract disorder	pathwayBased	0.162360550737552	170	194666	1722
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	upper digestive tract disorder	targetBased	0.191600561848195	5	339297	1446
HTS to identify specific small molecule inhibitors of Ras and Ras-related GTPases specifically Ras wildtype	HRAS	upper digestive tract disorder	targetBased	0.171768506342496	12	194628	267
HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress	DDIT3_inhibitors	upper digestive tract disorder	targetBased	0.135165226270177	7	218654	8241
AlphaScreen-based biochemical high throughput primary assay to identify inhibitors of microphthalmia-associated transcription factor (MITF)	MITF inhibitors	upper digestive tract disorder	targetBased	0.19148661159607	5	642362	5830
MITF Measured in Cell-Based System Using Plate Reader - 2084-01_Inhibitor_SinglePoint_HTS_Activity	MITF	upper digestive tract disorder	targetBased	0.19148661159607	5	331360	2760
HCS assay for microtubule stabilizers	TUBB	upper digestive tract disorder	targetBased	0.195319806594737	134	195821	1625
qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM)	BLM_inhibitors	upper digestive tract disorder	targetBased	0.187878760757735	7	347933	673
uHTS for identification of Inhibitors of Mdm2/MdmX interaction in luminescent format.	MDM4	upper digestive tract disorder	targetBased	0.142872648633855	6	331671	10022
Acumen qHTS Assay for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells: Sytravon	MTOR	upper digestive tract disorder	pathwayBased	0.198632349484476	156	43989	342
qHTS assay for re-activators of p53 using a Luc reporter	TP53	mouth mucosa disorder	pathwayBased	0.108038132958635	7	321427	201
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	mouth mucosa disorder	targetBased	0.108038132958635	7	54509	528
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53 Null Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	mouth mucosa disorder	targetBased	0.108038132958635	7	54513	338
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	mouth mucosa disorder	targetBased	0.108038132958635	7	125394	1890
qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature	nonSmallCellLungCarcinomaWithP53Mutations	mouth mucosa disorder	targetBased	0.108038132958635	7	124022	1156
Primary cell-based high throughput screening assay to measure STAT1 activation	STAT1 activation	Genetic intestinal disease	pathwayBased	0.139626497410024	5	195980	5134
Primary cell-based high throughput screening assay to measure STAT1 inhibition	STAT1	Genetic intestinal disease	targetBased	0.139626497410024	5	195980	695

Some of these associations have also gone through clinical trials, as those in the graph below.

Find clinical trials details in table. Use scroll bar or search funtion to select specific drugs, molecular targets or diseases.

BioAssay Name	program	gene	protName	diseaseName	molname	assayMode	clinicalPhase	clinicalStatus	studyStartDate	url	score	variantEffect	directionOnTrait	studyStopReason
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	anus disease	DILTIAZEM	targetBased	2	Not yet recruiting	01/06/2021	https://clinicaltrials.gov/study/NCT04887818	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	esophageal varices	PROPRANOLOL	targetBased	4	Unknown status	01/06/2013	https://clinicaltrials.gov/study/NCT02740166	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	esophageal varices	PROPRANOLOL	targetBased	3	Unknown status		https://clinicaltrials.gov/study/NCT01134692	0.7	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	dyspepsia	BUSPIRONE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03444831	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	dyspepsia	BUSPIRONE	targetBased	4	Completed	01/03/2016	https://clinicaltrials.gov/study/NCT03444831	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dysphagia	BUSPIRONE	targetBased	4	Recruiting	06/07/2021	https://clinicaltrials.gov/study/NCT05629325	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dysphagia	BUSPIRONE	targetBased	4	Recruiting	06/07/2021	https://clinicaltrials.gov/study/NCT05629325	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	gastroparesis	BUSPIRONE	targetBased	2	Completed	27/08/2019	https://clinicaltrials.gov/study/NCT03587142	0.2	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	gastroparesis	BUSPIRONE	targetBased	2	Completed	27/08/2019	https://clinicaltrials.gov/study/NCT03587142	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	gastroparesis	HALOPERIDOL	targetBased	4	Terminated	01/11/2012	https://clinicaltrials.gov/study/NCT02057549	1	LoF	protect	PI left institution
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	stomatitis	MORPHINE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01837446	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	stomatitis	MORPHINE	targetBased	2	Completed	01/07/2011	https://clinicaltrials.gov/study/NCT01837446	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01507246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01507246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE	targetBased	4	Terminated	01/12/2011	https://clinicaltrials.gov/study/NCT02058290	1	GoF	protect	Slower than expected enrollment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE	targetBased	4	Terminated	01/12/2011	https://clinicaltrials.gov/study/NCT02058290	1	GoF	protect	Slower than expected enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE	targetBased	4	Terminated	01/05/2012	https://clinicaltrials.gov/study/NCT01507233	1	GoF	protect	Slow enrollment.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE	targetBased	4	Terminated	01/05/2012	https://clinicaltrials.gov/study/NCT01507233	1	GoF	protect	Slow enrollment.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE	targetBased	4	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01507220	1	GoF	protect	Slow enrollment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE	targetBased	4	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01507220	1	GoF	protect	Slow enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastrointestinal disease	CODEINE	targetBased	4	Completed	07/09/2017	https://clinicaltrials.gov/study/NCT03784105	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastrointestinal disease	CODEINE	targetBased	4	Completed	07/09/2017	https://clinicaltrials.gov/study/NCT03784105	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	gastrointestinal disease	CODEINE	targetBased	4	Completed	07/09/2017	https://clinicaltrials.gov/study/NCT03784105	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastroesophageal reflux disease	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastroesophageal reflux disease	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastroesophageal reflux disease	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastroesophageal reflux disease	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastroesophageal reflux disease	PIRENZEPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A02BX03	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	NALOXONE	targetBased	4	Terminated	20/09/2017	https://clinicaltrials.gov/study/NCT03176316	1	LoF	protect	The study was terminated by the Institutional Review Board.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	NALOXONE	targetBased	4	Terminated	20/09/2017	https://clinicaltrials.gov/study/NCT03176316	1	LoF	protect	The study was terminated by the Institutional Review Board.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	ileus	NALOXONE	targetBased	4	Terminated	20/09/2017	https://clinicaltrials.gov/study/NCT03176316	1	LoF	protect	The study was terminated by the Institutional Review Board.
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	irritable bowel syndrome	NALOXONE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108446	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	NALOXONE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108446	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	NALOXONE	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108446	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	NALOXONE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	NALOXONE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	intestinal obstruction	NALOXONE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastric emptying	METOCLOPRAMIDE	targetBased	4	Completed	14/12/2022	https://clinicaltrials.gov/study/NCT05641051	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastric emptying	METOCLOPRAMIDE	targetBased	4	Completed	14/12/2022	https://clinicaltrials.gov/study/NCT05641051	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastric emptying	METOCLOPRAMIDE	targetBased	4	Completed	14/12/2022	https://clinicaltrials.gov/study/NCT05641051	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastric emptying	METOCLOPRAMIDE	targetBased	4	Completed	14/12/2022	https://clinicaltrials.gov/study/NCT05641051	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastric emptying	METOCLOPRAMIDE	targetBased	4	Completed	14/12/2022	https://clinicaltrials.gov/study/NCT05641051	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastric emptying	METOCLOPRAMIDE	targetBased	4	Completed	14/12/2022	https://clinicaltrials.gov/study/NCT05641051	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroschisis	METOCLOPRAMIDE	targetBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02098915	0.7	LoF	protect	Decision to prematurely close the trial was made because of poor recruitment.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroschisis	METOCLOPRAMIDE	targetBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02098915	0.7	LoF	protect	Decision to prematurely close the trial was made because of poor recruitment.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroschisis	METOCLOPRAMIDE	targetBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02098915	0.7	LoF	protect	Decision to prematurely close the trial was made because of poor recruitment.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroschisis	METOCLOPRAMIDE	targetBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02098915	0.7	LoF	protect	Decision to prematurely close the trial was made because of poor recruitment.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroschisis	METOCLOPRAMIDE	targetBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02098915	0.7	LoF	protect	Decision to prematurely close the trial was made because of poor recruitment.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroschisis	METOCLOPRAMIDE	targetBased	3	Terminated	01/03/2014	https://clinicaltrials.gov/study/NCT02098915	0.7	LoF	protect	Decision to prematurely close the trial was made because of poor recruitment.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	4	Completed	10/04/2021	https://clinicaltrials.gov/study/NCT04771481	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	4	Completed	10/04/2021	https://clinicaltrials.gov/study/NCT04771481	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	4	Completed	10/04/2021	https://clinicaltrials.gov/study/NCT04771481	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	4	Completed	10/04/2021	https://clinicaltrials.gov/study/NCT04771481	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	4	Completed	10/04/2021	https://clinicaltrials.gov/study/NCT04771481	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	4	Completed	10/04/2021	https://clinicaltrials.gov/study/NCT04771481	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	2	Recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT03840057	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	2	Recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT03840057	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	2	Recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT03840057	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	2	Recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT03840057	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	2	Recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT03840057	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	2	Recruiting	01/07/2020	https://clinicaltrials.gov/study/NCT03840057	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	3	Recruiting	16/03/2023	https://clinicaltrials.gov/study/NCT06297954	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	3	Recruiting	16/03/2023	https://clinicaltrials.gov/study/NCT06297954	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	3	Recruiting	16/03/2023	https://clinicaltrials.gov/study/NCT06297954	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	3	Recruiting	16/03/2023	https://clinicaltrials.gov/study/NCT06297954	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	3	Recruiting	16/03/2023	https://clinicaltrials.gov/study/NCT06297954	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Gastrointestinal hemorrhage	METOCLOPRAMIDE	targetBased	3	Recruiting	16/03/2023	https://clinicaltrials.gov/study/NCT06297954	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02025725	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02025725	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02025725	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02025725	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02025725	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	27/03/2014	https://clinicaltrials.gov/study/NCT02025725	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Completed	15/04/2022	https://clinicaltrials.gov/study/NCT05342818	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Completed	15/04/2022	https://clinicaltrials.gov/study/NCT05342818	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Completed	15/04/2022	https://clinicaltrials.gov/study/NCT05342818	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Completed	15/04/2022	https://clinicaltrials.gov/study/NCT05342818	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Completed	15/04/2022	https://clinicaltrials.gov/study/NCT05342818	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Completed	15/04/2022	https://clinicaltrials.gov/study/NCT05342818	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Terminated	04/04/2014	https://clinicaltrials.gov/study/NCT01934192	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Terminated	04/04/2014	https://clinicaltrials.gov/study/NCT01934192	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Terminated	04/04/2014	https://clinicaltrials.gov/study/NCT01934192	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Terminated	04/04/2014	https://clinicaltrials.gov/study/NCT01934192	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Terminated	04/04/2014	https://clinicaltrials.gov/study/NCT01934192	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	2	Terminated	04/04/2014	https://clinicaltrials.gov/study/NCT01934192	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02025751	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02025751	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02025751	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02025751	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02025751	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE	targetBased	3	Completed	01/04/2014	https://clinicaltrials.gov/study/NCT02025751	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	METOCLOPRAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA01	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	METOCLOPRAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	METOCLOPRAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA01	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	METOCLOPRAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	METOCLOPRAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA01	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	METOCLOPRAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA01	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT05876585	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT05876585	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT05876585	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT05876585	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT05876585	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Not yet recruiting	01/06/2024	https://clinicaltrials.gov/study/NCT05876585	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	intestinal obstruction	METOCLOPRAMIDE	targetBased	2	Terminated	26/06/2019	https://clinicaltrials.gov/study/NCT04027348	0.2	LoF	protect	low accrual
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	intestinal obstruction	METOCLOPRAMIDE	targetBased	2	Terminated	26/06/2019	https://clinicaltrials.gov/study/NCT04027348	0.2	LoF	protect	low accrual
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	intestinal obstruction	METOCLOPRAMIDE	targetBased	2	Terminated	26/06/2019	https://clinicaltrials.gov/study/NCT04027348	0.2	LoF	protect	low accrual
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	intestinal obstruction	METOCLOPRAMIDE	targetBased	2	Terminated	26/06/2019	https://clinicaltrials.gov/study/NCT04027348	0.2	LoF	protect	low accrual
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	intestinal obstruction	METOCLOPRAMIDE	targetBased	2	Terminated	26/06/2019	https://clinicaltrials.gov/study/NCT04027348	0.2	LoF	protect	low accrual
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	intestinal obstruction	METOCLOPRAMIDE	targetBased	2	Terminated	26/06/2019	https://clinicaltrials.gov/study/NCT04027348	0.2	LoF	protect	low accrual
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	METOCLOPRAMIDE	targetBased	4	Completed	26/04/2017	https://clinicaltrials.gov/study/NCT02907632	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	METOCLOPRAMIDE	targetBased	4	Completed	26/04/2017	https://clinicaltrials.gov/study/NCT02907632	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	METOCLOPRAMIDE	targetBased	4	Completed	26/04/2017	https://clinicaltrials.gov/study/NCT02907632	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	METOCLOPRAMIDE	targetBased	4	Completed	26/04/2017	https://clinicaltrials.gov/study/NCT02907632	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	METOCLOPRAMIDE	targetBased	4	Completed	26/04/2017	https://clinicaltrials.gov/study/NCT02907632	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	METOCLOPRAMIDE	targetBased	4	Completed	26/04/2017	https://clinicaltrials.gov/study/NCT02907632	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	3	Unknown status	01/11/2015	https://clinicaltrials.gov/study/NCT02619201	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Completed	30/01/2024	https://clinicaltrials.gov/study/NCT06390787	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Completed	30/01/2024	https://clinicaltrials.gov/study/NCT06390787	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Completed	30/01/2024	https://clinicaltrials.gov/study/NCT06390787	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Completed	30/01/2024	https://clinicaltrials.gov/study/NCT06390787	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Completed	30/01/2024	https://clinicaltrials.gov/study/NCT06390787	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Completed	30/01/2024	https://clinicaltrials.gov/study/NCT06390787	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE	targetBased	4	Completed	01/11/2012	https://clinicaltrials.gov/study/NCT02253524	1	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	gastrointestinal disease	PACLITAXEL	targetBased	2	Terminated	01/01/1996	https://clinicaltrials.gov/study/NCT00208936	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	salivary gland neoplasm	PACLITAXEL	targetBased	2	Recruiting	10/12/2021	https://clinicaltrials.gov/study/NCT05000892	0.2	LoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	salivary gland neoplasm	PACLITAXEL	targetBased	2	Not yet recruiting	30/04/2021	https://clinicaltrials.gov/study/NCT04825938	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
HCS assay for microtubule stabilizers	TUBB	TUBB	Tubulin beta chain	aphthous ulcer	COLCHICINE	targetBased	2	Unknown status	01/05/2007	https://clinicaltrials.gov/study/NCT00723268	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	diverticulitis	ACETAMINOPHEN	targetBased	4	Completed	01/11/2016	https://clinicaltrials.gov/study/NCT02785549	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	gastrointestinal disease	ACETAMINOPHEN	targetBased	2	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT02229786	0.2		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	intestinal obstruction	ACETAMINOPHEN	targetBased	4	Enrolling by invitation	11/10/2023	https://clinicaltrials.gov/study/NCT05878015	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	gastrointestinal mucositis	ACETAMINOPHEN	targetBased	4	Completed	01/02/2012	https://clinicaltrials.gov/study/NCT01822665	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Vomiting	ACETAMINOPHEN	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02462811	0.7		protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	FENTANYL	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108446	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	FENTANYL	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00108446	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastrointestinal disease	ALFENTANIL	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01199458	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastrointestinal disease	ALFENTANIL	targetBased	4	Completed	01/09/2010	https://clinicaltrials.gov/study/NCT01199458	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	dyspepsia	MIRTAZAPINE	targetBased	4	Completed	01/09/2006	https://clinicaltrials.gov/study/NCT01240096	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Gastrointestinal hemorrhage	EPINEPHRINE	targetBased	3	Completed	07/09/2015	https://clinicaltrials.gov/study/NCT02534571	0.7	GoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	Gastrointestinal hemorrhage	EPINEPHRINE	targetBased	4	Unknown status	01/09/2015	https://clinicaltrials.gov/study/NCT02537353	1	GoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	irritable bowel syndrome	ETHOSUXIMIDE	targetBased	2	Unknown status	30/04/2018	https://clinicaltrials.gov/study/NCT02973542	0.2	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	irritable bowel syndrome	ETHOSUXIMIDE	targetBased	3	Recruiting	01/11/2019	https://clinicaltrials.gov/study/NCT04217733	0.7	LoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	eosinophilic esophagitis	MESALAMINE	targetBased	2	Completed	09/02/2023	https://clinicaltrials.gov/study/NCT05488405	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	eosinophilic esophagitis	MESALAMINE	targetBased	2	Completed	09/02/2023	https://clinicaltrials.gov/study/NCT05488405	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	eosinophilic esophagitis	MESALAMINE	targetBased	2	Completed	09/02/2023	https://clinicaltrials.gov/study/NCT05488405	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	eosinophilic esophagitis	MESALAMINE	targetBased	2	Completed	09/02/2023	https://clinicaltrials.gov/study/NCT05488405	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	eosinophilic esophagitis	MESALAMINE	targetBased	2	Completed	09/02/2023	https://clinicaltrials.gov/study/NCT05488405	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	eosinophilic esophagitis	MESALAMINE	targetBased	2	Completed	09/02/2023	https://clinicaltrials.gov/study/NCT05488405	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT01120340	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT01120340	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT01120340	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT01120340	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT01120340	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	3	Completed	01/10/2005	https://clinicaltrials.gov/study/NCT01120340	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01534754	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01534754	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01534754	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01534754	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01534754	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticular disease	MESALAMINE	targetBased	4	Completed	01/01/2009	https://clinicaltrials.gov/study/NCT01534754	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gastrointestinal disease	MESALAMINE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02044952	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gastrointestinal disease	MESALAMINE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02044952	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gastrointestinal disease	MESALAMINE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02044952	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gastrointestinal disease	MESALAMINE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02044952	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gastrointestinal disease	MESALAMINE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02044952	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	gastrointestinal disease	MESALAMINE	targetBased	2	Unknown status	01/01/2014	https://clinicaltrials.gov/study/NCT02044952	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01177410	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01177410	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01177410	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01177410	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01177410	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/07/2010	https://clinicaltrials.gov/study/NCT01177410	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01412372	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01412372	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01412372	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01412372	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01412372	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/06/2010	https://clinicaltrials.gov/study/NCT01412372	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00626288	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00626288	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00626288	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00626288	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00626288	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	3	Completed	01/12/2007	https://clinicaltrials.gov/study/NCT00626288	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01316718	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01316718	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01316718	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01316718	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01316718	1	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Completed	01/03/2011	https://clinicaltrials.gov/study/NCT01316718	1	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01327300	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01327300	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01327300	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01327300	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01327300	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01327300	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01699438	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01699438	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01699438	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01699438	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01699438	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/04/2012	https://clinicaltrials.gov/study/NCT01699438	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00774007	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00774007	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00774007	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00774007	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00774007	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00774007	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Withdrawn	01/09/2014	https://clinicaltrials.gov/study/NCT02190526	1	GoF	protect	Study stopped due to lack of volunteer patients.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Withdrawn	01/09/2014	https://clinicaltrials.gov/study/NCT02190526	1	GoF	protect	Study stopped due to lack of volunteer patients.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Withdrawn	01/09/2014	https://clinicaltrials.gov/study/NCT02190526	1	GoF	protect	Study stopped due to lack of volunteer patients.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Withdrawn	01/09/2014	https://clinicaltrials.gov/study/NCT02190526	1	GoF	protect	Study stopped due to lack of volunteer patients.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Withdrawn	01/09/2014	https://clinicaltrials.gov/study/NCT02190526	1	GoF	protect	Study stopped due to lack of volunteer patients.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	irritable bowel syndrome	MESALAMINE	targetBased	4	Withdrawn	01/09/2014	https://clinicaltrials.gov/study/NCT02190526	1	GoF	protect	Study stopped due to lack of volunteer patients.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00695643	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00695643	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00695643	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00695643	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00695643	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2008	https://clinicaltrials.gov/study/NCT00695643	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01038739	0.35	GoF	protect	Stopped due to futility.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01038739	0.35	GoF	protect	Stopped due to futility.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01038739	0.35	GoF	protect	Stopped due to futility.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01038739	0.35	GoF	protect	Stopped due to futility.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01038739	0.35	GoF	protect	Stopped due to futility.
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Terminated	01/01/2010	https://clinicaltrials.gov/study/NCT01038739	0.35	GoF	protect	Stopped due to futility.
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554099	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554099	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554099	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554099	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554099	0.2	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	2	Completed	01/11/2007	https://clinicaltrials.gov/study/NCT00554099	0.2	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Completed	06/12/2007	https://clinicaltrials.gov/study/NCT00545103	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Completed	06/12/2007	https://clinicaltrials.gov/study/NCT00545103	0.7	GoF	protect
Measurement of TR-FRET detection format artefact in the screen for agonists of steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Completed	06/12/2007	https://clinicaltrials.gov/study/NCT00545103	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 1 (SRC-1) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Completed	06/12/2007	https://clinicaltrials.gov/study/NCT00545103	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 2 (SRC-2) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Completed	06/12/2007	https://clinicaltrials.gov/study/NCT00545103	0.7	GoF	protect
Primary biochemical High Throughput Screening assay for agonists of the steroid receptor coactivator 3 (SRC-3) recruitment by the peroxisome proliferator-activated receptor gamma (PPARgamma)	PPARG	PPARG	Peroxisome proliferator-activated receptor gamma	diverticulitis	MESALAMINE	targetBased	3	Completed	06/12/2007	https://clinicaltrials.gov/study/NCT00545103	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Vomiting	OLANZAPINE	targetBased	2	Recruiting	10/08/2017	https://clinicaltrials.gov/study/NCT03118986	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Vomiting	OLANZAPINE	targetBased	2	Recruiting	01/09/2018	https://clinicaltrials.gov/study/NCT03679182	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Vomiting	OLANZAPINE	targetBased	2	Terminated	01/07/2010	https://clinicaltrials.gov/study/NCT01148264	0.2	LoF	protect	poor enrolment
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	esophageal varices	CARVEDILOL	targetBased	4	Unknown status	01/12/2015	https://clinicaltrials.gov/study/NCT02638415	1	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	esophageal varices	CARVEDILOL	targetBased	2	Recruiting	01/10/2018	https://clinicaltrials.gov/study/NCT04499898	0.2	LoF	protect
HTS for Beta-2AR agonists via FAP method	ADRB2_activators	ADRB2	Beta-2 adrenergic receptor	esophageal varices	CARVEDILOL	targetBased	4	Recruiting	17/06/2019	https://clinicaltrials.gov/study/NCT03776955	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	ALIZAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA05	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	ALIZAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA05	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	ALIZAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA05	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	ALIZAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA05	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	ALIZAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA05	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	ALIZAPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA05	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8237f0-95a6-4163-b476-25c0509ef151	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8237f0-95a6-4163-b476-25c0509ef151	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be99224e-dd49-4628-a5bf-ed8469ffd4a4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be99224e-dd49-4628-a5bf-ed8469ffd4a4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7346bd7e-8af0-4de3-a6f8-0769b7a3135c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7346bd7e-8af0-4de3-a6f8-0769b7a3135c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a66d2f97-8d22-482d-b18b-f58f1d882f42	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a66d2f97-8d22-482d-b18b-f58f1d882f42	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5efdfc41-a7a4-43cf-858a-7da8ea1399ad	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5efdfc41-a7a4-43cf-858a-7da8ea1399ad	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c97152f0-73ae-4463-8177-8f9250d84252	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c97152f0-73ae-4463-8177-8f9250d84252	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT02340481	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT02340481	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1985ce5e-1209-495e-94c9-03d6e2832627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1985ce5e-1209-495e-94c9-03d6e2832627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d358a9c1-47fa-424c-8cc0-24010cfb7ee3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d358a9c1-47fa-424c-8cc0-24010cfb7ee3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146e0229-1444-4ad8-8d31-1b02c4222df0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146e0229-1444-4ad8-8d31-1b02c4222df0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00685607	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4	Completed	01/10/2008	https://clinicaltrials.gov/study/NCT00685607	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6deb0658-c96e-40bd-b3a3-9655a4769270	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6deb0658-c96e-40bd-b3a3-9655a4769270	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d98f5f8-abab-4f30-90ad-19e030de2a76	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d98f5f8-abab-4f30-90ad-19e030de2a76	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c4a072e-88e6-4c35-adf2-fe81f3bcf4c9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c4a072e-88e6-4c35-adf2-fe81f3bcf4c9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35df0cb2-ca82-49ee-afad-4431db5708d6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35df0cb2-ca82-49ee-afad-4431db5708d6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72a7ae47-cdf3-4949-b9f8-f29b153f787f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72a7ae47-cdf3-4949-b9f8-f29b153f787f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf47ac3-746f-47c3-82b2-32ac979ff963	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf47ac3-746f-47c3-82b2-32ac979ff963	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fdf0f19-a8d3-408c-adcb-dcaa0a4c2741	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fdf0f19-a8d3-408c-adcb-dcaa0a4c2741	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d23f73b-afc2-448d-afb3-b167d02cfc06	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d23f73b-afc2-448d-afb3-b167d02cfc06	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9b96a5d-2754-4958-b066-c2e65f71dbb0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9b96a5d-2754-4958-b066-c2e65f71dbb0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01434d38-2c9d-4222-adb8-cf7b4909cac8	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01434d38-2c9d-4222-adb8-cf7b4909cac8	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6a3322d-943c-4f7a-9975-94d3fa38b12c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6a3322d-943c-4f7a-9975-94d3fa38b12c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad71d4ab-d293-47a2-8f3f-2c9f42d76e40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad71d4ab-d293-47a2-8f3f-2c9f42d76e40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc639a62-8bc9-44bd-a07f-639079e30331	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc639a62-8bc9-44bd-a07f-639079e30331	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	3	Completed	26/03/1997	https://clinicaltrials.gov/study/NCT00003057	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	3	Completed	26/03/1997	https://clinicaltrials.gov/study/NCT00003057	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2038ce27-2b16-44be-8d57-ebd6dbaebf26	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2038ce27-2b16-44be-8d57-ebd6dbaebf26	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00292344	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00292344	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3310a3c2-389a-4b27-a478-67c905789854	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3310a3c2-389a-4b27-a478-67c905789854	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b43dded-bf30-4967-b78f-8111a2f28979	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b43dded-bf30-4967-b78f-8111a2f28979	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=853f76d1-eb22-4fad-8d72-46d11b538f89	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=853f76d1-eb22-4fad-8d72-46d11b538f89	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	3	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00650637	0.7	GoF	protect	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There were no safety concerns that led to the decision to terminate.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	3	Terminated	01/01/2003	https://clinicaltrials.gov/study/NCT00650637	0.7	GoF	protect	The study was prematurely discontinued due to administrative reasons on August 18, 2003. There were no safety concerns that led to the decision to terminate.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7e0fc3-334f-4c7d-a661-486efd030717	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7e0fc3-334f-4c7d-a661-486efd030717	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c2f4b11-6c45-4270-9b0b-ce73d5eae65f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c2f4b11-6c45-4270-9b0b-ce73d5eae65f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a1429b-cd24-4cb7-84bb-5ec7a7b2b687	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a1429b-cd24-4cb7-84bb-5ec7a7b2b687	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00359970	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4	Completed	01/06/2002	https://clinicaltrials.gov/study/NCT00359970	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00807326	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00807326	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=580e6cd4-3f05-4996-9dc3-c50d757ae210	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=580e6cd4-3f05-4996-9dc3-c50d757ae210	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39deeb78-f9c3-421e-8455-ff5ab6820718	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39deeb78-f9c3-421e-8455-ff5ab6820718	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7e5f53-e587-411b-a0ec-b32452ec0d21	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7e5f53-e587-411b-a0ec-b32452ec0d21	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6615a259-98ee-4d07-adc0-8d7f490e19f7	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6615a259-98ee-4d07-adc0-8d7f490e19f7	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a64b9fed-bf27-4e02-876e-72a628a0d8ef	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a64b9fed-bf27-4e02-876e-72a628a0d8ef	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37a300a8-8c4e-46ff-bbff-857384c4a640	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37a300a8-8c4e-46ff-bbff-857384c4a640	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd0d20c-7c02-47d9-b20e-412b0e5dfe8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd0d20c-7c02-47d9-b20e-412b0e5dfe8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8143434f-070b-43ea-8af9-30d142765b18	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8143434f-070b-43ea-8af9-30d142765b18	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab07bfd1-d2d3-427a-866d-89a10d40a4e9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab07bfd1-d2d3-427a-866d-89a10d40a4e9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fecal incontinence	LOPERAMIDE	targetBased	3	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02008565	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fecal incontinence	LOPERAMIDE	targetBased	3	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02008565	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fecal incontinence	LOPERAMIDE	targetBased	2	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00727649	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fecal incontinence	LOPERAMIDE	targetBased	2	Completed	01/07/2008	https://clinicaltrials.gov/study/NCT00727649	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fecal incontinence	LOPERAMIDE	targetBased	4	Withdrawn	01/10/2009	https://clinicaltrials.gov/study/NCT00933465	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fecal incontinence	LOPERAMIDE	targetBased	4	Withdrawn	01/10/2009	https://clinicaltrials.gov/study/NCT00933465	1	GoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	burning mouth syndrome	CAPSAICIN	targetBased	4	Recruiting	01/11/2023	https://clinicaltrials.gov/study/NCT06040190	1		protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	Vomiting	CAPSAICIN	targetBased	2	Completed	20/12/2017	https://clinicaltrials.gov/study/NCT03223350	0.2		protect
Inhibitors of the vitamin D receptor (VDR): qHTS	VDR	VDR	Vitamin D3 receptor	irritable bowel syndrome	CHOLECALCIFEROL	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02026518	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of the mouse 5-hydroxytryptamine (serotonin) receptor 2A (HTR2A)	HTR2A	HTR2A	5-hydroxytryptamine receptor 2A	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	Vomiting	DROPERIDOL	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT00702442	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DICYCLOMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA07	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DICYCLOMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA07	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DICYCLOMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA07	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DICYCLOMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA07	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DICYCLOMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA07	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	CLEBOPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA06	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	CLEBOPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	CLEBOPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA06	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	CLEBOPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA06	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	CLEBOPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA06	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	CLEBOPRIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA06	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE BROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE BROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE BROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE BROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE BROMIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
High Throughput Screening for Cocaine Antagonists: Primary Screen	SLC6A3	SLC6A3	Sodium-dependent dopamine transporter	Dysphagia	MODAFINIL	targetBased	2	Completed	01/03/2010	https://clinicaltrials.gov/study/NCT01085903	0.2	LoF	protect
HTS Assay for Compounds that Act as Agonists of the Vanilloid Receptor 1	TRPV1	TRPV1	Transient receptor potential cation channel subfamily V member 1	irritable bowel syndrome	SB-705498	targetBased	2	Terminated	26/01/2007	https://clinicaltrials.gov/study/NCT00461682	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02264587	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02264587	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02264587	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02264587	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02264587	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	4	Unknown status	01/10/2014	https://clinicaltrials.gov/study/NCT02264587	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Recruiting	27/03/2023	https://clinicaltrials.gov/study/NCT05832151	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Recruiting	27/03/2023	https://clinicaltrials.gov/study/NCT05832151	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Recruiting	27/03/2023	https://clinicaltrials.gov/study/NCT05832151	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Recruiting	27/03/2023	https://clinicaltrials.gov/study/NCT05832151	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Recruiting	27/03/2023	https://clinicaltrials.gov/study/NCT05832151	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Recruiting	27/03/2023	https://clinicaltrials.gov/study/NCT05832151	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	3	Withdrawn	01/03/2010	https://clinicaltrials.gov/study/NCT01378884	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	3	Withdrawn	01/03/2010	https://clinicaltrials.gov/study/NCT01378884	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	3	Withdrawn	01/03/2010	https://clinicaltrials.gov/study/NCT01378884	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	3	Withdrawn	01/03/2010	https://clinicaltrials.gov/study/NCT01378884	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	3	Withdrawn	01/03/2010	https://clinicaltrials.gov/study/NCT01378884	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	3	Withdrawn	01/03/2010	https://clinicaltrials.gov/study/NCT01378884	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00760461	0.2	LoF	protect	Enrolled subjects were unable to receive drug from dispensing pharmacy.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00760461	0.2	LoF	protect	Enrolled subjects were unable to receive drug from dispensing pharmacy.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00760461	0.2	LoF	protect	Enrolled subjects were unable to receive drug from dispensing pharmacy.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00760461	0.2	LoF	protect	Enrolled subjects were unable to receive drug from dispensing pharmacy.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00760461	0.2	LoF	protect	Enrolled subjects were unable to receive drug from dispensing pharmacy.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	01/10/2008	https://clinicaltrials.gov/study/NCT00760461	0.2	LoF	protect	Enrolled subjects were unable to receive drug from dispensing pharmacy.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Enrolling by invitation	01/05/2015	https://clinicaltrials.gov/study/NCT02757534	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Enrolling by invitation	01/05/2015	https://clinicaltrials.gov/study/NCT02757534	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Enrolling by invitation	01/05/2015	https://clinicaltrials.gov/study/NCT02757534	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Enrolling by invitation	01/05/2015	https://clinicaltrials.gov/study/NCT02757534	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Enrolling by invitation	01/05/2015	https://clinicaltrials.gov/study/NCT02757534	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Enrolling by invitation	01/05/2015	https://clinicaltrials.gov/study/NCT02757534	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	17/02/2020	https://clinicaltrials.gov/study/NCT04208698	0.2	LoF	protect	Trial was terminated due to the impact of COVID-19 on trial activities.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	17/02/2020	https://clinicaltrials.gov/study/NCT04208698	0.2	LoF	protect	Trial was terminated due to the impact of COVID-19 on trial activities.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	17/02/2020	https://clinicaltrials.gov/study/NCT04208698	0.2	LoF	protect	Trial was terminated due to the impact of COVID-19 on trial activities.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	17/02/2020	https://clinicaltrials.gov/study/NCT04208698	0.2	LoF	protect	Trial was terminated due to the impact of COVID-19 on trial activities.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	17/02/2020	https://clinicaltrials.gov/study/NCT04208698	0.2	LoF	protect	Trial was terminated due to the impact of COVID-19 on trial activities.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Terminated	17/02/2020	https://clinicaltrials.gov/study/NCT04208698	0.2	LoF	protect	Trial was terminated due to the impact of COVID-19 on trial activities.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Completed	11/09/2019	https://clinicaltrials.gov/study/NCT04026997	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Completed	11/09/2019	https://clinicaltrials.gov/study/NCT04026997	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Completed	11/09/2019	https://clinicaltrials.gov/study/NCT04026997	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Completed	11/09/2019	https://clinicaltrials.gov/study/NCT04026997	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Completed	11/09/2019	https://clinicaltrials.gov/study/NCT04026997	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	DOMPERIDONE	targetBased	2	Completed	11/09/2019	https://clinicaltrials.gov/study/NCT04026997	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	DOMPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA03	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	DOMPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	DOMPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA03	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	DOMPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	DOMPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA03	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	DOMPERIDONE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03FA03	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	DOMPERIDONE	targetBased	3	Terminated	07/12/2015	https://clinicaltrials.gov/study/NCT02699385	0.35	LoF	protect	Study prematurely terminated upon recommendation of IDMC due to lack of efficacy.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	DOMPERIDONE	targetBased	3	Terminated	07/12/2015	https://clinicaltrials.gov/study/NCT02699385	0.35	LoF	protect	Study prematurely terminated upon recommendation of IDMC due to lack of efficacy.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	DOMPERIDONE	targetBased	3	Terminated	07/12/2015	https://clinicaltrials.gov/study/NCT02699385	0.35	LoF	protect	Study prematurely terminated upon recommendation of IDMC due to lack of efficacy.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	DOMPERIDONE	targetBased	3	Terminated	07/12/2015	https://clinicaltrials.gov/study/NCT02699385	0.35	LoF	protect	Study prematurely terminated upon recommendation of IDMC due to lack of efficacy.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	DOMPERIDONE	targetBased	3	Terminated	07/12/2015	https://clinicaltrials.gov/study/NCT02699385	0.35	LoF	protect	Study prematurely terminated upon recommendation of IDMC due to lack of efficacy.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	DOMPERIDONE	targetBased	3	Terminated	07/12/2015	https://clinicaltrials.gov/study/NCT02699385	0.35	LoF	protect	Study prematurely terminated upon recommendation of IDMC due to lack of efficacy.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	26/06/2019	https://clinicaltrials.gov/study/NCT05030116	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	26/06/2019	https://clinicaltrials.gov/study/NCT05030116	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	26/06/2019	https://clinicaltrials.gov/study/NCT05030116	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	26/06/2019	https://clinicaltrials.gov/study/NCT05030116	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	26/06/2019	https://clinicaltrials.gov/study/NCT05030116	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	26/06/2019	https://clinicaltrials.gov/study/NCT05030116	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	27/08/2018	https://clinicaltrials.gov/study/NCT03617016	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	27/08/2018	https://clinicaltrials.gov/study/NCT03617016	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	27/08/2018	https://clinicaltrials.gov/study/NCT03617016	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	27/08/2018	https://clinicaltrials.gov/study/NCT03617016	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	27/08/2018	https://clinicaltrials.gov/study/NCT03617016	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	4	Completed	27/08/2018	https://clinicaltrials.gov/study/NCT03617016	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01355276	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01355276	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01355276	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01355276	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01355276	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	DOMPERIDONE	targetBased	3	Completed	01/10/2010	https://clinicaltrials.gov/study/NCT01355276	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	3	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01710462	0.7	LoF	protect	Change of company's strategy
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	3	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01710462	0.7	LoF	protect	Change of company's strategy
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	3	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01710462	0.7	LoF	protect	Change of company's strategy
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	3	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01710462	0.7	LoF	protect	Change of company's strategy
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	3	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01710462	0.7	LoF	protect	Change of company's strategy
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	3	Withdrawn	01/08/2013	https://clinicaltrials.gov/study/NCT01710462	0.7	LoF	protect	Change of company's strategy
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Withdrawn	01/03/2018	https://clinicaltrials.gov/study/NCT03355170	1	LoF	protect	The sponsor decided to continue with a different design and a different protocol.
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Withdrawn	01/03/2018	https://clinicaltrials.gov/study/NCT03355170	1	LoF	protect	The sponsor decided to continue with a different design and a different protocol.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Withdrawn	01/03/2018	https://clinicaltrials.gov/study/NCT03355170	1	LoF	protect	The sponsor decided to continue with a different design and a different protocol.
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Withdrawn	01/03/2018	https://clinicaltrials.gov/study/NCT03355170	1	LoF	protect	The sponsor decided to continue with a different design and a different protocol.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Withdrawn	01/03/2018	https://clinicaltrials.gov/study/NCT03355170	1	LoF	protect	The sponsor decided to continue with a different design and a different protocol.
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Withdrawn	01/03/2018	https://clinicaltrials.gov/study/NCT03355170	1	LoF	protect	The sponsor decided to continue with a different design and a different protocol.
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02958046	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02958046	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02958046	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02958046	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02958046	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Completed	01/01/2014	https://clinicaltrials.gov/study/NCT02958046	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02140073	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02140073	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02140073	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02140073	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02140073	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroesophageal reflux disease	DOMPERIDONE	targetBased	4	Unknown status	01/12/2013	https://clinicaltrials.gov/study/NCT02140073	1	LoF	protect
Primary cell-based high throughput assay for inhibitors of the Janus kinase 2 mutant JAK2V617F	JAK2	JAK2	Tyrosine-protein kinase , Tyrosine-protein kinase JAK2	pouchitis	TOFACITINIB	targetBased	2	Terminated	25/01/2021	https://clinicaltrials.gov/study/NCT04580277	0.2	LoF	protect	low recruitment
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	Vomiting	HYDROCODONE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02462811	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Vomiting	HYDROCODONE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02462811	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Vomiting	HYDROCODONE	targetBased	3	Completed	01/09/2014	https://clinicaltrials.gov/study/NCT02462811	0.7	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	short bowel syndrome	EXENATIDE	targetBased	4	Withdrawn	01/03/2013	https://clinicaltrials.gov/study/NCT01818648	1	GoF	protect	Study was withdrawn by PI due to decision to study a different medication.
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	short bowel syndrome	EXENATIDE	targetBased	4	Withdrawn	01/03/2013	https://clinicaltrials.gov/study/NCT01818648	1	GoF	protect	Study was withdrawn by PI due to decision to study a different medication.
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	short bowel syndrome	EXENATIDE	targetBased	4	Withdrawn	01/03/2013	https://clinicaltrials.gov/study/NCT01818648	1	GoF	protect	Study was withdrawn by PI due to decision to study a different medication.
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	gastrointestinal disease	ALVERINE	targetBased	2			https://www.whocc.no/atc_ddd_index/?code=A03AX58	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	gastrointestinal disease	ALVERINE	targetBased	2			https://www.whocc.no/atc_ddd_index/?code=A03AX58	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	gastrointestinal disease	ALVERINE	targetBased	2			https://www.whocc.no/atc_ddd_index/?code=A03AX08	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	gastrointestinal disease	ALVERINE	targetBased	2			https://www.whocc.no/atc_ddd_index/?code=A03AX08	0.2	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	irritable bowel syndrome	ALVERINE	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00542295	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	irritable bowel syndrome	ALVERINE	targetBased	4	Completed	01/07/2007	https://clinicaltrials.gov/study/NCT00542295	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	irritable bowel syndrome	ALVERINE	targetBased	4	Completed	03/09/2018	https://clinicaltrials.gov/study/NCT04145856	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	irritable bowel syndrome	ALVERINE	targetBased	4	Completed	03/09/2018	https://clinicaltrials.gov/study/NCT04145856	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	irritable bowel syndrome	ALVERINE	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01404923	1	LoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	irritable bowel syndrome	ALVERINE	targetBased	4	Completed	01/12/2009	https://clinicaltrials.gov/study/NCT01404923	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	BROMOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA04	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	BROMOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA04	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	BROMOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA04	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	BROMOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA04	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	BROMOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA04	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	BROMOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA04	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	BROMOPRIDE	targetBased	3	Completed	17/01/2017	https://clinicaltrials.gov/study/NCT02604576	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	BROMOPRIDE	targetBased	3	Completed	17/01/2017	https://clinicaltrials.gov/study/NCT02604576	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	BROMOPRIDE	targetBased	3	Completed	17/01/2017	https://clinicaltrials.gov/study/NCT02604576	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	BROMOPRIDE	targetBased	3	Completed	17/01/2017	https://clinicaltrials.gov/study/NCT02604576	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	BROMOPRIDE	targetBased	3	Completed	17/01/2017	https://clinicaltrials.gov/study/NCT02604576	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	BROMOPRIDE	targetBased	3	Completed	17/01/2017	https://clinicaltrials.gov/study/NCT02604576	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENCYCLIMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA01	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENCYCLIMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENCYCLIMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA01	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENCYCLIMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENCYCLIMINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AA01	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	HYDROMORPHONE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00600158	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	HYDROMORPHONE	targetBased	3	Completed	01/04/2005	https://clinicaltrials.gov/study/NCT00600158	0.7	GoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	anus disease	NIFEDIPINE	targetBased	2	Not yet recruiting	01/06/2021	https://clinicaltrials.gov/study/NCT04887818	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00205842	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Completed	01/06/2004	https://clinicaltrials.gov/study/NCT00205842	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00388479	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Completed	01/12/2001	https://clinicaltrials.gov/study/NCT00388479	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	4	Terminated	01/09/2017	https://clinicaltrials.gov/study/NCT03068975	1	LoF	protect	This study was terminated due to failure to enroll, a low volume of patients met criteria.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	4	Terminated	01/09/2017	https://clinicaltrials.gov/study/NCT03068975	1	LoF	protect	This study was terminated due to failure to enroll, a low volume of patients met criteria.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	4	Recruiting	01/08/2020	https://clinicaltrials.gov/study/NCT04405037	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	4	Recruiting	01/08/2020	https://clinicaltrials.gov/study/NCT04405037	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Terminated	02/12/2015	https://clinicaltrials.gov/study/NCT02742181	0.7	LoF	protect	terminated due to lack of enrollment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Terminated	02/12/2015	https://clinicaltrials.gov/study/NCT02742181	0.7	LoF	protect	terminated due to lack of enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00388401	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Completed	01/01/2002	https://clinicaltrials.gov/study/NCT00388401	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00708201	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	4	Completed	01/03/2009	https://clinicaltrials.gov/study/NCT00708201	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00388258	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	3	Completed	01/03/2001	https://clinicaltrials.gov/study/NCT00388258	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	2	Terminated	08/03/2018	https://clinicaltrials.gov/study/NCT03352414	0.2	LoF	protect	stopped by sponsor
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	ALVIMOPAN	targetBased	2	Terminated	08/03/2018	https://clinicaltrials.gov/study/NCT03352414	0.2	LoF	protect	stopped by sponsor
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00259922	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00259922	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00101998	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	2	Completed	01/10/2003	https://clinicaltrials.gov/study/NCT00101998	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00135577	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	2	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00135577	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00241722	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00241722	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00256932	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	ALVIMOPAN	targetBased	3	Completed	01/08/2005	https://clinicaltrials.gov/study/NCT00256932	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03BA01	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03BA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03BA01	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03BA01	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ATROPINE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03BA01	1	LoF	protect
Homogeneous Time-Resolved Fluorescence Resonance Energy Transfer (HTRF) Assay	CACNA1B_modulators	CACNA1B	Voltage-dependent N-type calcium channel subunit alpha-1D	gastrointestinal disease	PHLOROGLUCINOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AX12	1	LoF	protect
Inhibitors of Cav3 T-type Calcium Channels: Primary Screen	CACNA1H_inhibitors	CACNA1H	Voltage-dependent T-type calcium channel subunit alpha-1H	gastrointestinal disease	PHLOROGLUCINOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AX12	1	LoF	protect
HTS for Inhibition of CaV1.3 ICDI/IQ interaction using a live-cell FRET assay Measured in Cell-Based System Using Plate Reader - 7081-01_Inhibitor_SinglePoint_HTS_Activity	CACNA1D_inhibitors	CACNA1D	Voltage-dependent N-type calcium channel subunit alpha-1B	gastrointestinal disease	PHLOROGLUCINOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AX12	1	LoF	protect
Modulation of AMPAR-stargazin complexes	AMPAStargazinComplexModulators	CACNG2	Voltage-dependent calcium channel gamma-2 subunit	gastrointestinal disease	PHLOROGLUCINOL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AX12	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	MEPENZOLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB12	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	MEPENZOLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB12	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	MEPENZOLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB12	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	MEPENZOLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB12	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	MEPENZOLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB12	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00807326	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/11/2008	https://clinicaltrials.gov/study/NCT00807326	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6deb0658-c96e-40bd-b3a3-9655a4769270	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6deb0658-c96e-40bd-b3a3-9655a4769270	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT02340481	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	3	Completed	01/07/2005	https://clinicaltrials.gov/study/NCT02340481	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6615a259-98ee-4d07-adc0-8d7f490e19f7	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6615a259-98ee-4d07-adc0-8d7f490e19f7	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd0d20c-7c02-47d9-b20e-412b0e5dfe8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9dd0d20c-7c02-47d9-b20e-412b0e5dfe8f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5efdfc41-a7a4-43cf-858a-7da8ea1399ad	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5efdfc41-a7a4-43cf-858a-7da8ea1399ad	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b43dded-bf30-4967-b78f-8111a2f28979	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=4b43dded-bf30-4967-b78f-8111a2f28979	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d98f5f8-abab-4f30-90ad-19e030de2a76	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5d98f5f8-abab-4f30-90ad-19e030de2a76	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7e5f53-e587-411b-a0ec-b32452ec0d21	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7e5f53-e587-411b-a0ec-b32452ec0d21	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	3	Completed	26/03/1997	https://clinicaltrials.gov/study/NCT00003057	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	3	Completed	26/03/1997	https://clinicaltrials.gov/study/NCT00003057	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8143434f-070b-43ea-8af9-30d142765b18	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8143434f-070b-43ea-8af9-30d142765b18	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2038ce27-2b16-44be-8d57-ebd6dbaebf26	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2038ce27-2b16-44be-8d57-ebd6dbaebf26	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6a3322d-943c-4f7a-9975-94d3fa38b12c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c6a3322d-943c-4f7a-9975-94d3fa38b12c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab07bfd1-d2d3-427a-866d-89a10d40a4e9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ab07bfd1-d2d3-427a-866d-89a10d40a4e9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72a7ae47-cdf3-4949-b9f8-f29b153f787f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72a7ae47-cdf3-4949-b9f8-f29b153f787f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9b96a5d-2754-4958-b066-c2e65f71dbb0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f9b96a5d-2754-4958-b066-c2e65f71dbb0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c97152f0-73ae-4463-8177-8f9250d84252	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c97152f0-73ae-4463-8177-8f9250d84252	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39deeb78-f9c3-421e-8455-ff5ab6820718	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39deeb78-f9c3-421e-8455-ff5ab6820718	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be99224e-dd49-4628-a5bf-ed8469ffd4a4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=be99224e-dd49-4628-a5bf-ed8469ffd4a4	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c2f4b11-6c45-4270-9b0b-ce73d5eae65f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c2f4b11-6c45-4270-9b0b-ce73d5eae65f	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146e0229-1444-4ad8-8d31-1b02c4222df0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=146e0229-1444-4ad8-8d31-1b02c4222df0	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3310a3c2-389a-4b27-a478-67c905789854	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3310a3c2-389a-4b27-a478-67c905789854	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a64b9fed-bf27-4e02-876e-72a628a0d8ef	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a64b9fed-bf27-4e02-876e-72a628a0d8ef	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a1429b-cd24-4cb7-84bb-5ec7a7b2b687	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=03a1429b-cd24-4cb7-84bb-5ec7a7b2b687	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a66d2f97-8d22-482d-b18b-f58f1d882f42	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a66d2f97-8d22-482d-b18b-f58f1d882f42	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7e0fc3-334f-4c7d-a661-486efd030717	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3f7e0fc3-334f-4c7d-a661-486efd030717	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf47ac3-746f-47c3-82b2-32ac979ff963	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8bf47ac3-746f-47c3-82b2-32ac979ff963	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad71d4ab-d293-47a2-8f3f-2c9f42d76e40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ad71d4ab-d293-47a2-8f3f-2c9f42d76e40	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37a300a8-8c4e-46ff-bbff-857384c4a640	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=37a300a8-8c4e-46ff-bbff-857384c4a640	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=853f76d1-eb22-4fad-8d72-46d11b538f89	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=853f76d1-eb22-4fad-8d72-46d11b538f89	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d23f73b-afc2-448d-afb3-b167d02cfc06	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d23f73b-afc2-448d-afb3-b167d02cfc06	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=580e6cd4-3f05-4996-9dc3-c50d757ae210	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=580e6cd4-3f05-4996-9dc3-c50d757ae210	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c4a072e-88e6-4c35-adf2-fe81f3bcf4c9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c4a072e-88e6-4c35-adf2-fe81f3bcf4c9	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35df0cb2-ca82-49ee-afad-4431db5708d6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=35df0cb2-ca82-49ee-afad-4431db5708d6	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1985ce5e-1209-495e-94c9-03d6e2832627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1985ce5e-1209-495e-94c9-03d6e2832627	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fdf0f19-a8d3-408c-adcb-dcaa0a4c2741	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5fdf0f19-a8d3-408c-adcb-dcaa0a4c2741	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01434d38-2c9d-4222-adb8-cf7b4909cac8	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=01434d38-2c9d-4222-adb8-cf7b4909cac8	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d358a9c1-47fa-424c-8cc0-24010cfb7ee3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d358a9c1-47fa-424c-8cc0-24010cfb7ee3	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7346bd7e-8af0-4de3-a6f8-0769b7a3135c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7346bd7e-8af0-4de3-a6f8-0769b7a3135c	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8237f0-95a6-4163-b476-25c0509ef151	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ae8237f0-95a6-4163-b476-25c0509ef151	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc639a62-8bc9-44bd-a07f-639079e30331	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	Diarrhea	LOPERAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=cc639a62-8bc9-44bd-a07f-639079e30331	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fecal incontinence	LOPERAMIDE HYDROCHLORIDE	targetBased	4	Withdrawn	01/10/2009	https://clinicaltrials.gov/study/NCT00933465	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	fecal incontinence	LOPERAMIDE HYDROCHLORIDE	targetBased	4	Withdrawn	01/10/2009	https://clinicaltrials.gov/study/NCT00933465	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	NALOXONE HYDROCHLORIDE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	NALOXONE HYDROCHLORIDE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	intestinal obstruction	NALOXONE HYDROCHLORIDE	targetBased	3	Unknown status	01/05/2000	https://clinicaltrials.gov/study/NCT00020605	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	intestinal disease	SCOPOLAMINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01929044	0.7	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	intestinal disease	SCOPOLAMINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01929044	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	intestinal disease	SCOPOLAMINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01929044	0.7	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	intestinal disease	SCOPOLAMINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01929044	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	intestinal disease	SCOPOLAMINE	targetBased	3	Completed	01/08/2013	https://clinicaltrials.gov/study/NCT01929044	0.7	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	SCOPOLAMINE	targetBased	2	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT02229786	0.2	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	SCOPOLAMINE	targetBased	2	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT02229786	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	SCOPOLAMINE	targetBased	2	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT02229786	0.2	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	SCOPOLAMINE	targetBased	2	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT02229786	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	SCOPOLAMINE	targetBased	2	Completed	01/02/1998	https://clinicaltrials.gov/study/NCT02229786	0.2	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Vomiting	SCOPOLAMINE	targetBased	4	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT04785118	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Vomiting	SCOPOLAMINE	targetBased	4	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT04785118	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Vomiting	SCOPOLAMINE	targetBased	4	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT04785118	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Vomiting	SCOPOLAMINE	targetBased	4	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT04785118	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Vomiting	SCOPOLAMINE	targetBased	4	Completed	01/10/2021	https://clinicaltrials.gov/study/NCT04785118	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	PROPANTHELINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=84a920c8-b637-4741-b9b2-fc607e245ce0	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE	targetBased	2	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT01367548	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE	targetBased	2	Completed	01/07/2003	https://clinicaltrials.gov/study/NCT01367548	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE	targetBased	2	Completed	21/02/2019	https://clinicaltrials.gov/study/NCT03852524	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE	targetBased	2	Completed	21/02/2019	https://clinicaltrials.gov/study/NCT03852524	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE	targetBased	3	Completed	17/10/2007	https://clinicaltrials.gov/study/NCT00528970	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE	targetBased	3	Completed	17/10/2007	https://clinicaltrials.gov/study/NCT00528970	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE	targetBased	3	Completed	31/10/2006	https://clinicaltrials.gov/study/NCT00401375	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE	targetBased	3	Completed	31/10/2006	https://clinicaltrials.gov/study/NCT00401375	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastrointestinal disease	METHYLNALTREXONE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01012960	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastrointestinal disease	METHYLNALTREXONE	targetBased	4	Completed	01/11/2009	https://clinicaltrials.gov/study/NCT01012960	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastroparesis	METHYLNALTREXONE	targetBased	2	Terminated	01/05/2010	https://clinicaltrials.gov/study/NCT01117376	0.2	LoF	protect	The study was prematurely terminated because of unavailibility of Methylnaltrexone in the region
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastroparesis	METHYLNALTREXONE	targetBased	2	Terminated	01/05/2010	https://clinicaltrials.gov/study/NCT01117376	0.2	LoF	protect	The study was prematurely terminated because of unavailibility of Methylnaltrexone in the region
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	METHYLNALTREXONE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00387309	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	METHYLNALTREXONE	targetBased	3	Completed	01/12/2006	https://clinicaltrials.gov/study/NCT00387309	0.7	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	ileus	ASIMADOLINE	targetBased	2	Terminated	01/01/2007	https://clinicaltrials.gov/study/NCT00443040	0.2	GoF	protect	poor enrollment (31 of a planned 114 subjects were randomized and evaluable)
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	irritable bowel syndrome	ASIMADOLINE	targetBased	3	Completed	01/05/2010	https://clinicaltrials.gov/study/NCT01100684	0.7	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	irritable bowel syndrome	ASIMADOLINE	targetBased	2	Completed	01/08/2006	https://clinicaltrials.gov/study/NCT00454688	0.2	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	irritable bowel syndrome	ASIMADOLINE	targetBased	2	Completed	01/01/2005	https://clinicaltrials.gov/study/NCT00955994	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	radiation-induced gastrointestinal mucositis	PILOCARPINE HYDROCHLORIDE	targetBased	3	Completed	01/03/1998	https://clinicaltrials.gov/study/NCT00003139	0.7	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) agonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dysphagia	BUSPIRONE HYDROCHLORIDE	targetBased	4	Recruiting	06/07/2021	https://clinicaltrials.gov/study/NCT05629325	1	GoF	protect
Primary HTS assay for 5-Hydroxytryptamine (Serotonin) Receptor Subtype 1a (5HT1a) antagonists	HTR1A	HTR1A	5-hydroxytryptamine receptor 1A	Dysphagia	BUSPIRONE HYDROCHLORIDE	targetBased	4	Recruiting	06/07/2021	https://clinicaltrials.gov/study/NCT05629325	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=676078a3-13e5-cc32-e053-2a91aa0ac75f	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	irritable bowel syndrome	DICYCLOMINE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=058b8aa0-0c23-430a-a8fd-0191106fd9e8	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	ileus	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/10/2018	https://clinicaltrials.gov/study/NCT05669781	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroenteritis	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01165866	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	3	Terminated	01/09/2009	https://clinicaltrials.gov/study/NCT00869310	0.7	LoF	protect	we terminated the study before enrolling 303/560 due to a slow accrual
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	Vomiting	METOCLOPRAMIDE HYDROCHLORIDE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=94e5acdf-f19c-749a-e053-2995a90ae451	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM BROMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM BROMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM BROMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM BROMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	CLIDINIUM BROMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03CA02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRROLATE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastrointestinal disease	CODEINE PHOSPHATE	targetBased	4	Completed	07/09/2017	https://clinicaltrials.gov/study/NCT03784105	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	gastrointestinal disease	CODEINE PHOSPHATE	targetBased	4	Completed	07/09/2017	https://clinicaltrials.gov/study/NCT03784105	1	GoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	gastrointestinal disease	CODEINE PHOSPHATE	targetBased	4	Completed	07/09/2017	https://clinicaltrials.gov/study/NCT03784105	1	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ISOPROPAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB09	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ISOPROPAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB09	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ISOPROPAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB09	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ISOPROPAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB09	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	ISOPROPAMIDE	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB09	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB03	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB03	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB03	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB53	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB53	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB53	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB53	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	OXYPHENONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB53	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	HEXOCYCLIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB10	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	HEXOCYCLIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB10	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	HEXOCYCLIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB10	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	HEXOCYCLIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB10	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	HEXOCYCLIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB10	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	GLYCOPYRRONIUM	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB02	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DIPHEMANIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB15	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DIPHEMANIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB15	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DIPHEMANIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB15	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DIPHEMANIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB15	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	DIPHEMANIL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB15	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	TRIDIHEXETHYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB08	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	TRIDIHEXETHYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB08	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	TRIDIHEXETHYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB08	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	TRIDIHEXETHYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB08	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	gastrointestinal disease	TRIDIHEXETHYL	targetBased	4			https://www.whocc.no/atc_ddd_index/?code=A03AB08	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE BROMIDE	targetBased	3	Completed	17/10/2007	https://clinicaltrials.gov/study/NCT00528970	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	METHYLNALTREXONE BROMIDE	targetBased	3	Completed	17/10/2007	https://clinicaltrials.gov/study/NCT00528970	0.7	LoF	protect
Factor XIIa 1536 HTS	F12_modulation	F12	Coagulation factor XII	flatulence	BISMUTH SUBGALLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=fb6ad16b-caac-4a63-a10e-99808a6a83e7	1	GoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	pouchitis	VEDOLIZUMAB	targetBased	3	Not yet recruiting	25/06/2024	https://clinicaltrials.gov/study/NCT06443502	0.7	LoF	protect
HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library	ITGA4	ITGA4	Integrin alpha-4	pouchitis	VEDOLIZUMAB	targetBased	4	Completed	12/10/2016	https://clinicaltrials.gov/study/NCT02790138	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE SULFATE	targetBased	4	Terminated	01/05/2012	https://clinicaltrials.gov/study/NCT01507233	1	GoF	protect	Slow enrollment.
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE SULFATE	targetBased	4	Terminated	01/05/2012	https://clinicaltrials.gov/study/NCT01507233	1	GoF	protect	Slow enrollment.
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE SULFATE	targetBased	4	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01507220	1	GoF	protect	Slow enrollment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE SULFATE	targetBased	4	Terminated	01/03/2012	https://clinicaltrials.gov/study/NCT01507220	1	GoF	protect	Slow enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE SULFATE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01507246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE SULFATE	targetBased	4	Completed	01/12/2011	https://clinicaltrials.gov/study/NCT01507246	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE SULFATE	targetBased	4	Terminated	01/12/2011	https://clinicaltrials.gov/study/NCT02058290	1	GoF	protect	Slower than expected enrollment
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	intestinal obstruction	MORPHINE SULFATE	targetBased	4	Terminated	01/12/2011	https://clinicaltrials.gov/study/NCT02058290	1	GoF	protect	Slower than expected enrollment
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	constipation disorder	NALDEMEDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	constipation disorder	NALDEMEDINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	NALDEMEDINE	targetBased	2	Completed	19/05/2010	https://clinicaltrials.gov/study/NCT01122030	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	bowel dysfunction	NALDEMEDINE	targetBased	2	Completed	19/05/2010	https://clinicaltrials.gov/study/NCT01122030	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	irritable bowel syndrome	ITOPRIDE	targetBased	2	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01027260	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	irritable bowel syndrome	ITOPRIDE	targetBased	2	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01027260	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	irritable bowel syndrome	ITOPRIDE	targetBased	2	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01027260	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	irritable bowel syndrome	ITOPRIDE	targetBased	2	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01027260	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	irritable bowel syndrome	ITOPRIDE	targetBased	2	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01027260	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	irritable bowel syndrome	ITOPRIDE	targetBased	2	Completed	01/06/2008	https://clinicaltrials.gov/study/NCT01027260	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	ITOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA07	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastrointestinal disease	ITOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA07	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	ITOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA07	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastrointestinal disease	ITOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA07	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	ITOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA07	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastrointestinal disease	ITOPRIDE	targetBased	3			https://www.whocc.no/atc_ddd_index/?code=A03FA07	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112177	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112177	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112177	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112177	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112177	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112177	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00110968	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00110968	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00110968	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00110968	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00110968	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/09/2004	https://clinicaltrials.gov/study/NCT00110968	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	2	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00272103	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	2	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00272103	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	2	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00272103	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	2	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00272103	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	2	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00272103	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	2	Completed	01/12/2000	https://clinicaltrials.gov/study/NCT00272103	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Completed	22/02/2013	https://clinicaltrials.gov/study/NCT04647955	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Completed	22/02/2013	https://clinicaltrials.gov/study/NCT04647955	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Completed	22/02/2013	https://clinicaltrials.gov/study/NCT04647955	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Completed	22/02/2013	https://clinicaltrials.gov/study/NCT04647955	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Completed	22/02/2013	https://clinicaltrials.gov/study/NCT04647955	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Completed	22/02/2013	https://clinicaltrials.gov/study/NCT04647955	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00112203	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00112203	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00112203	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00112203	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00112203	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/11/2004	https://clinicaltrials.gov/study/NCT00112203	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112190	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112190	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112190	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112190	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112190	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	3	Completed	01/07/2004	https://clinicaltrials.gov/study/NCT00112190	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Recruiting	18/11/2021	https://clinicaltrials.gov/study/NCT04918017	1	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Recruiting	18/11/2021	https://clinicaltrials.gov/study/NCT04918017	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Recruiting	18/11/2021	https://clinicaltrials.gov/study/NCT04918017	1	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Recruiting	18/11/2021	https://clinicaltrials.gov/study/NCT04918017	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Recruiting	18/11/2021	https://clinicaltrials.gov/study/NCT04918017	1	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	dyspepsia	ITOPRIDE	targetBased	4	Recruiting	18/11/2021	https://clinicaltrials.gov/study/NCT04918017	1	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	peritonitis	ITOPRIDE	targetBased	3	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT04161768	0.7	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	peritonitis	ITOPRIDE	targetBased	3	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT04161768	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	peritonitis	ITOPRIDE	targetBased	3	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT04161768	0.7	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	peritonitis	ITOPRIDE	targetBased	3	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT04161768	0.7	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	peritonitis	ITOPRIDE	targetBased	3	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT04161768	0.7	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	peritonitis	ITOPRIDE	targetBased	3	Recruiting	01/12/2018	https://clinicaltrials.gov/study/NCT04161768	0.7	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	4	Terminated	20/08/2020	https://clinicaltrials.gov/study/NCT04486326	1	LoF	protect	low enrollment
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	4	Terminated	20/08/2020	https://clinicaltrials.gov/study/NCT04486326	1	LoF	protect	low enrollment
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf	1	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547898	0.7	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547898	0.7	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00002408	0.7	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00002408	0.7	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45584fba-8081-4cd1-a21e-3ea8237f62ff	1	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	Anoctamin-1	Diarrhea	CROFELEMER	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45584fba-8081-4cd1-a21e-3ea8237f62ff	1	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	Anoctamin-1	Chronic diarrhea	CROFELEMER	targetBased	4	Recruiting	01/04/2019	https://clinicaltrials.gov/study/NCT03898856	1	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	Anoctamin-1	Chronic diarrhea	CROFELEMER	targetBased	4	Recruiting	01/04/2019	https://clinicaltrials.gov/study/NCT03898856	1	LoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00002408	0.7	LoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	3	Completed		https://clinicaltrials.gov/study/NCT00002408	0.7	LoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547898	0.7	LoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	3	Completed	01/10/2007	https://clinicaltrials.gov/study/NCT00547898	0.7	LoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf	1	LoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	4			https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202292s000lbl.pdf	1	LoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45584fba-8081-4cd1-a21e-3ea8237f62ff	1	LoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=45584fba-8081-4cd1-a21e-3ea8237f62ff	1	LoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	4	Terminated	20/08/2020	https://clinicaltrials.gov/study/NCT04486326	1	LoF	protect	low enrollment
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	Diarrhea	CROFELEMER	targetBased	4	Terminated	20/08/2020	https://clinicaltrials.gov/study/NCT04486326	1	LoF	protect	low enrollment
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	Chronic diarrhea	CROFELEMER	targetBased	4	Recruiting	01/04/2019	https://clinicaltrials.gov/study/NCT03898856	1	LoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	Chronic diarrhea	CROFELEMER	targetBased	4	Recruiting	01/04/2019	https://clinicaltrials.gov/study/NCT03898856	1	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A)	ANO1_inhibitors	ANO1	Anoctamin-1	irritable bowel syndrome	CROFELEMER	targetBased	2	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00461526	0.2	LoF	protect
Primary cell-based high-throughput screening for identification of compounds that activate/potentiate calcium-activated chloride channels (TMEM16A)	ANO1_activators	ANO1	Anoctamin-1	irritable bowel syndrome	CROFELEMER	targetBased	2	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00461526	0.2	LoF	protect
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	irritable bowel syndrome	CROFELEMER	targetBased	2	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00461526	0.2	LoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	irritable bowel syndrome	CROFELEMER	targetBased	2	Completed	01/10/2006	https://clinicaltrials.gov/study/NCT00461526	0.2	LoF	protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn6) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	gastrointestinal disease	FIBRINOGEN, HUMAN	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01589822	0.2		protect
Fluorescence polarization-based biochemical primary high throughput screening assay to identify inhibitors that disrupt the binding of a cyclic peptide (Tn7) to the fibrin proteolytic product D-Dimer and fragment E complex [DD(E )]	FGB_inhibitors	FGB	Fibrinogen beta chain [Cleaved into: Fibrinopeptide B; Fibrinogen beta chain]	gastrointestinal disease	FIBRINOGEN, HUMAN	targetBased	2	Completed	01/06/2012	https://clinicaltrials.gov/study/NCT01589822	0.2		protect
Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R)	AVPR1A_agonists	AVPR1A	Vasopressin V1a receptor	esophageal varices	TERLIPRESSIN	targetBased	4	Completed	01/02/2014	https://clinicaltrials.gov/study/NCT02119884	1		protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=78e42769-061f-4973-ac3a-dc3fcc4bf641	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=786b9c9a-8b70-41bb-9ea3-0bf6dd7a06df	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=559269eb-4a0f-4b38-8d7d-70d419b96a0e	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	Peptic ulcer	ATROPINE SULFATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=350dcd54-857d-4a65-9fd0-ad54f090fd7b	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diarrheal disease	ELUXADOLINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/truberzi	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	diarrheal disease	ELUXADOLINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/truberzi	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	3	Completed	29/05/2012	https://clinicaltrials.gov/study/NCT01553747	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	3	Completed	29/05/2012	https://clinicaltrials.gov/study/NCT01553747	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7821bd40-4c84-4984-951b-6436ae20421a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7821bd40-4c84-4984-951b-6436ae20421a	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	3	Completed	29/05/2012	https://clinicaltrials.gov/study/NCT01553591	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	3	Completed	29/05/2012	https://clinicaltrials.gov/study/NCT01553591	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	2	Recruiting	15/11/2017	https://clinicaltrials.gov/study/NCT03339128	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	2	Recruiting	15/11/2017	https://clinicaltrials.gov/study/NCT03339128	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	2	Completed	28/04/2010	https://clinicaltrials.gov/study/NCT01130272	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	2	Completed	28/04/2010	https://clinicaltrials.gov/study/NCT01130272	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/truberzi	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	4			https://www.ema.europa.eu/en/medicines/human/EPAR/truberzi	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	4	Completed	23/02/2018	https://clinicaltrials.gov/study/NCT03441581	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	4	Completed	23/02/2018	https://clinicaltrials.gov/study/NCT03441581	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	3	Enrolling by invitation	13/08/2021	https://clinicaltrials.gov/study/NCT04880876	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	3	Enrolling by invitation	13/08/2021	https://clinicaltrials.gov/study/NCT04880876	0.7	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	4	Completed	25/10/2016	https://clinicaltrials.gov/study/NCT02959983	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ELUXADOLINE	targetBased	4	Completed	25/10/2016	https://clinicaltrials.gov/study/NCT02959983	1	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	constipation disorder	NALOXEGOL OXALATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c02665d-05d2-4e99-b403-c270de543ebe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	constipation disorder	NALOXEGOL OXALATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c02665d-05d2-4e99-b403-c270de543ebe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	constipation disorder	NALOXEGOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c02665d-05d2-4e99-b403-c270de543ebe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	constipation disorder	NALOXEGOL	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5c02665d-05d2-4e99-b403-c270de543ebe	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	NALOXEGOL	targetBased	3	Completed	14/10/2020	https://clinicaltrials.gov/study/NCT04433390	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	ileus	NALOXEGOL	targetBased	3	Completed	14/10/2020	https://clinicaltrials.gov/study/NCT04433390	0.7	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	constipation disorder	NALDEMEDINE TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16	1	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	constipation disorder	NALDEMEDINE TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b1a1256c-a1eb-4abe-ab1e-30e4711afd16	1	LoF	protect
Primary Cell-Based Assay to Identify Agonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	eosinophilic esophagitis	ETRASIMOD	targetBased	2	Completed	15/12/2020	https://clinicaltrials.gov/study/NCT04682639	0.2		protect
Primary Cell-Based Assay to Identify Antagonists of the Sphingosine 1-Phosphate Receptor 4 (S1P4)	S1PR4	S1PR4	Sphingosine 1-phosphate receptor 4	eosinophilic esophagitis	ETRASIMOD	targetBased	2	Completed	15/12/2020	https://clinicaltrials.gov/study/NCT04682639	0.2		protect
Primary HTS and Confirmation Assays for S1P1 Agonists and Agonism Potentiators	S1PR1	S1PR1	Sphingosine 1-phosphate receptor 1	eosinophilic esophagitis	ETRASIMOD	targetBased	2	Completed	15/12/2020	https://clinicaltrials.gov/study/NCT04682639	0.2	GoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 1 (CHRM1)	CHRM1_agonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Discovery of Novel Allosteric Modulators of the M1 Muscarinic Receptor: Agonist Primary Screen	CHRM1_allosteric_activators	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human M1 muscarinic receptor (CHRM1).	CHRM1_PAMs	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Discovery of novel allosteric modulators of the M1 muscarinic receptor: Antagonist Primary Screen	CHRM1_allosteric_antagonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human M1 muscarinic receptor (CHRM1)	CHRM1_antgonists	CHRM1	Muscarinic acetylcholine receptor M1	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 5 (CHRM5)	CHRM5	CHRM5	Muscarinic acetylcholine receptor M5	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2189f3f5-39dc-4e85-b7c6-9515ded59686	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=26cdd84d-ffa0-4e52-b359-4acef4bd8093	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify positive allosteric modulators (PAMs) of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_PAMs	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_antgonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
Fluorescence-based cell-based primary high throughput screening assay to identify agonists of the human cholinergic receptor, muscarinic 4 (CHRM4)	CHRM4_agonists	CHRM4	Muscarinic acetylcholine receptor M4	peptic ulcer disease	GLYCOPYRRONIUM TOSYLATE	targetBased	4			https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=38f88829-a226-4810-866c-1b62c47e8aee	1	LoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	pouchitis	LIRAGLUTIDE	targetBased	2	Completed	22/03/2022	https://clinicaltrials.gov/study/NCT04763564	0.2	GoF	protect
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	pouchitis	LIRAGLUTIDE	targetBased	2	Completed	22/03/2022	https://clinicaltrials.gov/study/NCT04763564	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	pouchitis	LIRAGLUTIDE	targetBased	2	Completed	22/03/2022	https://clinicaltrials.gov/study/NCT04763564	0.2	GoF	protect
qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode)	GLP1R	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	short bowel syndrome	LIRAGLUTIDE	targetBased	2	Withdrawn	20/10/2017	https://clinicaltrials.gov/study/NCT03371862	0.2	GoF	protect	No participants recruited. Not able to recruit due to COVID 19.
qHTS of GLP-1 Receptor Agonists	GLP1R agonists	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	short bowel syndrome	LIRAGLUTIDE	targetBased	2	Withdrawn	20/10/2017	https://clinicaltrials.gov/study/NCT03371862	0.2	GoF	protect	No participants recruited. Not able to recruit due to COVID 19.
qHTS of GLP-1 Receptor Inverse Agonists: (PAM Mode) (Taking the negative queue for PAMs)	GLP1R PAMs	GLP1R	Glucagon-like peptide 1 receptor , Glucagon-like peptide-1 receptor	short bowel syndrome	LIRAGLUTIDE	targetBased	2	Withdrawn	20/10/2017	https://clinicaltrials.gov/study/NCT03371862	0.2	GoF	protect	No participants recruited. Not able to recruit due to COVID 19.
Identification of Small Molecule Correctors of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Delta508 Mutation Function in Human Bronchial Epithelial Cells. Measured in Cell-Based System Using Plate Reader - 7017-01_Other_SinglePoint_HTS_Activity	cftrCorrectors	CFTR	Cystic fibrosis transmembrane conductance regulator	gastrointestinal disease	IOWH-032	targetBased	2	Completed	04/11/2019	https://clinicaltrials.gov/study/NCT04150250	0.2	LoF	protect
Fluorescence Polarization with CAL-PDZ Measured in Biochemical System Using Plate Reader - 2109-02_Inhibitor_SinglePoint_HTS_Activity	cftrTrafficModulators	CFTR	Cystic fibrosis transmembrane conductance regulator	gastrointestinal disease	IOWH-032	targetBased	2	Completed	04/11/2019	https://clinicaltrials.gov/study/NCT04150250	0.2	LoF	protect
uHTS identification of small molecule antagonists of the kappa opioid receptor via a luminescent beta-arrestin assay	OPRK1	OPRK1	Kappa-type opioid receptor	irritable bowel syndrome	ORP-101	targetBased	2	Completed	22/11/2019	https://clinicaltrials.gov/study/NCT04129619	0.2	LoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ORP-101	targetBased	2	Completed	22/11/2019	https://clinicaltrials.gov/study/NCT04129619	0.2	GoF	protect
Luminescence-based cell-based primary high throughput screening assay to identify inverse agonists of heterodimerization of the mu 1 (OPRM1) and delta 1 (OPRD1) opioid receptors	OPRM1	OPRM1	Mu-type opioid receptor	irritable bowel syndrome	ORP-101	targetBased	2	Completed	22/11/2019	https://clinicaltrials.gov/study/NCT04129619	0.2	GoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	TRAZPIROBEN	targetBased	2	Completed	14/10/2018	https://clinicaltrials.gov/study/NCT03544229	0.2	LoF	protect
HTS Assay for Allosteric Agonists of the Human D2 Dopamine Receptor: Primary Screen for Agonists	D2_agonists	DRD2	Dopaminereceptor2	gastroparesis	TRAZPIROBEN	targetBased	2	Completed	14/10/2018	https://clinicaltrials.gov/study/NCT03544229	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	TRAZPIROBEN	targetBased	2	Completed	14/10/2018	https://clinicaltrials.gov/study/NCT03544229	0.2	LoF	protect
HTS Assay for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Primary Screen for Potentiators	D2_PAMs	DRD2	Dopaminereceptor2	gastroparesis	TRAZPIROBEN	targetBased	2	Completed	14/10/2018	https://clinicaltrials.gov/study/NCT03544229	0.2	LoF	protect
Beta-Arrestin HTS for Positive Allosteric Modulators of the Human D2 Dopamine Receptor: Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	TRAZPIROBEN	targetBased	2	Completed	14/10/2018	https://clinicaltrials.gov/study/NCT03544229	0.2	LoF	protect
HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Primary Screen for Antagonists	D2_antagonists	DRD2	Dopaminereceptor2	gastroparesis	TRAZPIROBEN	targetBased	2	Completed	14/10/2018	https://clinicaltrials.gov/study/NCT03544229	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Antagonist: qHTS	D3_antagonists	DRD3	Dopaminereceptor3	gastroparesis	TRAZPIROBEN	targetBased	2	Completed	14/10/2018	https://clinicaltrials.gov/study/NCT03544229	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Agonist: qHTS	D3_agonists	DRD3	Dopaminereceptor3	gastroparesis	TRAZPIROBEN	targetBased	2	Completed	14/10/2018	https://clinicaltrials.gov/study/NCT03544229	0.2	LoF	protect
qHTS of D3 Dopamine Receptor Potentiators: qHTS	D3_PAMs	DRD3	Dopaminereceptor3	gastroparesis	TRAZPIROBEN	targetBased	2	Completed	14/10/2018	https://clinicaltrials.gov/study/NCT03544229	0.2	LoF	protect

Partner with DrTarget for AI-Optimized Screening

We welcome collaborations with biotech companies, research institutions, and pharmaceutical partners looking to leverage AI for drug discovery. Get in touch to explore custom screening solutions and accelerate your research.